

Tau is a candidate gene for chromosome 17 frontotemporal

Annals of Neurology

43, 815-825

DOI: [10.1002/ana.410430617](https://doi.org/10.1002/ana.410430617)

Citation Report

#	ARTICLE	IF	CITATIONS
2	Genetic dissection of Alzheimer's disease and related dementias: amyloid and its relationship to tau. <i>Nature Neuroscience</i> , 1998, 1, 355-358.	7.1	310
3	Tau in Alzheimer's disease. <i>Trends in Cell Biology</i> , 1998, 8, 425-427.	3.6	526
4	Neuropathology of Dementing Disorders. <i>Trends in Neurosciences</i> , 1998, 21, 497-498.	4.2	0
5	Tau protein pathology in neurodegenerative diseases. <i>Trends in Neurosciences</i> , 1998, 21, 428-433.	4.2	652
6	Filamentous nerve cell inclusions in neurodegenerative diseases. <i>Current Opinion in Neurobiology</i> , 1998, 8, 619-632.	2.0	247
7	Tau Mutations Cause Frontotemporal Dementias. <i>Neuron</i> , 1998, 21, 955-958.	3.8	294
8	Synthetic filaments assembled from C-terminally truncated $\hat{\text{I}}\pm$ -synuclein. <i>FEBS Letters</i> , 1998, 436, 309-312.	1.3	373
9	Tau proteins with FTDP-17 mutations have a reduced ability to promote microtubule assembly. <i>FEBS Letters</i> , 1998, 437, 207-210.	1.3	440
10	Genetic Classification of Primary Neurodegenerative Disease. , 1998, 282, 1075-1079.		297
11	ALZHEIMER'S DISEASE: Genetic Studies and Transgenic Models. <i>Annual Review of Genetics</i> , 1998, 32, 461-493.	3.2	384
12	Potential therapeutic targets for Alzheimer's disease. <i>Expert Opinion on Therapeutic Targets</i> , 1998, 2, 157-179.	1.0	6
13	The 77-kDa Echinoderm Microtubule-Associated Protein (EMAP) Shares Epitopes with the Mammalian Brain MAPs, MAP-2 and Tau. <i>Biochemical and Biophysical Research Communications</i> , 1998, 250, 502-505.	1.0	5
14	Tau Pathology in Two Dutch Families with Mutations in the Microtubule-Binding Region of Tau. <i>American Journal of Pathology</i> , 1998, 153, 1359-1363.	1.9	268
15	Frontotemporal lobar degeneration. <i>Neurology</i> , 1998, 51, 1546-1554.	1.5	4,852
16	Pathogenic implications of mutations in the tau gene in pallido-ponto-nigral degeneration and related neurodegenerative disorders linked to chromosome 17. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 1998, 95, 13103-13107.	3.3	502
17	Segregation of a Missense Mutation in the Microtubule-Associated Protein Tau Gene with Familial Frontotemporal Dementia and Parkinsonism. <i>Human Molecular Genetics</i> , 1998, 7, 1825-1829.	1.4	258
18	Genetic Epidemiology of Parkinson's Disease. <i>Journal of Geriatric Psychiatry and Neurology</i> , 1998, 11, 98-106.	1.2	38
19	Frontotemporal Dementia Genetics. <i>Journal of Geriatric Psychiatry and Neurology</i> , 1998, 11, 55-60.	1.2	8

#	ARTICLE	IF	CITATIONS
20	Clinical and Genetic Aspects of Progressive Supranuclear Palsy. Journal of Geriatric Psychiatry and Neurology, 1998, 11, 107-114.	1.2	30
21	Mutation in the tau gene in familial multiple system tauopathy with presenile dementia. Proceedings of the National Academy of Sciences of the United States of America, 1998, 95, 7737-7741.	3.3	1,479
22	Tau Mutations in Frontotemporal Dementia. Dementia and Geriatric Cognitive Disorders, 1999, 10, 88-92.	0.7	25
23	Inheritance of Frontotemporal Dementia. Archives of Neurology, 1999, 56, 817.	4.9	197
24	A clinical pathological comparison of three families with frontotemporal dementia and identical mutations in the tau gene (P301L). Brain, 1999, 122, 741-756.	3.7	214
25	Introduction to Alzheimer's Disease. , 2000, 32, 1-22.		3
26	Tau Phosphorylation Both In Vitro and in Cells. , 2000, 32, 375-394.		1
27	The tangled biology of tau. Proceedings of the National Academy of Sciences of the United States of America, 1999, 96, 7120-7121.	3.3	28
28	Deamidation and Isoaspartate Formation in Smearred Tau in Paired Helical Filaments. Journal of Biological Chemistry, 1999, 274, 7368-7378.	1.6	104
29	Structure of tau exon 10 splicing regulatory element RNA and destabilization by mutations of frontotemporal dementia and parkinsonism linked to chromosome 17. Proceedings of the National Academy of Sciences of the United States of America, 1999, 96, 8229-8234.	3.3	241
30	Mutational analysis of the tau gene in progressive supranuclear palsy. Neurology, 1999, 53, 1421-1421.	1.5	51
31	The tau gene A0 polymorphism in progressive supranuclear palsy and related neurodegenerative diseases. Journal of Neurology, Neurosurgery and Psychiatry, 1999, 66, 665-667.	0.9	103
32	<i>Tau</i> Immunoreactivity Detected in Human Plasma, But No Obvious Increase in Dementia. Dementia and Geriatric Cognitive Disorders, 1999, 10, 442-445.	0.7	31
33	Association of an Extended Haplotype in the Tau Gene with Progressive Supranuclear Palsy. Human Molecular Genetics, 1999, 8, 711-715.	1.4	749
34	5â€² Splice Site Mutations in tau Associated with the Inherited Dementia FTDP-17 Affect a Stem-Loop Structure That Regulates Alternative Splicing of Exon 10. Journal of Biological Chemistry, 1999, 274, 15134-15143.	1.6	266
35	The genetics of disorders with synuclein pathology and parkinsonism. Human Molecular Genetics, 1999, 8, 1901-1905.	1.4	36
36	Introduction: Pick's disease and frontotemporal dementia. Neuropathology, 1999, 19, 417-421.	0.7	3
37	Frontotemporal dementia with tauopathy: A review and preliminary immunohistochemical study of tau kinases and phosphatases. Neuropathology, 1999, 19, 433-440.	0.7	1

#	ARTICLE	IF	CITATIONS
38	REVIEW: tau protein pathology in Alzheimer's disease and related disorders. <i>Neuropathology and Applied Neurobiology</i> , 1999, 25, 171-187.	1.8	181
39	Mechanisms of damage to myelin and oligodendrocytes and their relevance to disease. <i>Neuropathology and Applied Neurobiology</i> , 1999, 25, 435-458.	1.8	96
40	Comparative Biochemistry of Tau in Progressive Supranuclear Palsy, Corticobasal Degeneration, FTDP τ 17 and Pick's Disease. <i>Brain Pathology</i> , 1999, 9, 681-693.	2.1	327
41	Fibrillogenesis of Tau: Insights from Tau Missense Mutations in FTDP τ 17. <i>Brain Pathology</i> , 1999, 9, 695-705.	2.1	43
42	Transgenic Models of Tauopathies and Synucleinopathies. <i>Brain Pathology</i> , 1999, 9, 733-739.	2.1	31
43	Translating cell biology into therapeutic advances in Alzheimer's disease. <i>Nature</i> , 1999, 399, A23-A31.	13.7	1,368
44	Tau gene mutation in familial progressive subcortical gliosis. <i>Nature Medicine</i> , 1999, 5, 454-457.	15.2	189
46	Microtubule-associated protein tau, heparan sulphate and α -synuclein in several neurodegenerative diseases with dementia. <i>Acta Neuropathologica</i> , 1999, 97, 585-594.	3.9	71
47	Neuronal and glial DNA fragmentation in Pick's disease. <i>Acta Neuropathologica</i> , 1999, 98, 55-61.	3.9	25
48	A mutation at codon 279 (N279K) in exon 10 of the Tau gene causes a tauopathy with dementia and supranuclear palsy. <i>Acta Neuropathologica</i> , 1999, 98, 62-77.	3.9	174
49	A familial case of Alzheimer's disease without tau pathology may be linked with chromosome 3 markers. <i>Human Genetics</i> , 1999, 105, 32-37.	1.8	29
50	Neuropsychiatric aspects of frontotemporal dementias. <i>Current Psychiatry Reports</i> , 1999, 1, 93-98.	2.1	13
51	Neurodegenerative disease: a different view of diagnosis. <i>Trends in Molecular Medicine</i> , 1999, 5, 514-517.	2.6	19
53	Mutation in the tau exon 10 splice site region in familial frontotemporal dementia. <i>Annals of Neurology</i> , 1999, 45, 270-271.	2.8	43
54	Tangles and plaques in nondemented aging and ?preclinical? Alzheimer's disease. <i>Annals of Neurology</i> , 1999, 45, 358-368.	2.8	1,569
55	From genotype to phenotype: A clinical, pathological, and biochemical investigation of frontotemporal dementia and parkinsonism (FTDP-17) caused by the P301L tau mutation. <i>Annals of Neurology</i> , 1999, 45, 704-715.	2.8	128
56	Frequency of tau mutations in three series of non-Alzheimer's degenerative dementia. <i>Annals of Neurology</i> , 1999, 46, 243-248.	2.8	150
57	Overexpression of four-repeat tau mRNA isoforms in progressive supranuclear palsy but not in Alzheimer's disease. <i>Annals of Neurology</i> , 1999, 46, 325-332.	2.8	140

#	ARTICLE	IF	CITATIONS
58	Phenotypic variation in hereditary frontotemporal dementia with tau mutations. <i>Annals of Neurology</i> , 1999, 46, 617-626.	2.8	221
59	FTDP-17: An early-onset phenotype with parkinsonism and epileptic seizures caused by a novel mutation. <i>Annals of Neurology</i> , 1999, 46, 708-715.	2.8	190
60	Neurofibrillary tangle parkinsonian disorders?tau pathology andtau genetics. <i>Movement Disorders</i> , 1999, 14, 731-736.	2.2	40
61	Molecular Basis of the Neurodegenerative Disorders. <i>New England Journal of Medicine</i> , 1999, 340, 1970-1980.	13.9	380
62	Tau protein as a therapeutic target in Alzheimer's disease and other neurodegenerative disorders. <i>Expert Opinion on Therapeutic Patents</i> , 1999, 9, 1359-1370.	2.4	7
63	Missense and silent tau gene mutations cause frontotemporal dementia with parkinsonism-chromosome 17 type, by affecting multiple alternative RNA splicing regulatory elements. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 1999, 96, 5598-5603.	3.3	501
64	TOXIC NEURONAL APOPTOSIS AND MODIFICATIONS OF TAU AND APP GENE AND PROTEIN EXPRESSIONS*. <i>Drug Metabolism Reviews</i> , 1999, 31, 635-647.	1.5	23
65	High Prevalence of Mutations in the Microtubule-Associated Protein Tau in a Population Study of Frontotemporal Dementia in the Netherlands. <i>American Journal of Human Genetics</i> , 1999, 64, 414-421.	2.6	410
66	Molecular genetics of familial parkinsonism. <i>Parkinsonism and Related Disorders</i> , 1999, 5, 145-155.	1.1	8
67	Genetics of Parkinson's disease. <i>Biomedicine and Pharmacotherapy</i> , 1999, 53, 109-116.	2.5	30
68	Neurodegenerative Tauopathies. <i>Neuron</i> , 1999, 24, 507-510.	3.8	1,603
69	Age-Dependent Emergence and Progression of a Tauopathy in Transgenic Mice Overexpressing the Shortest Human Tau Isoform. <i>Neuron</i> , 1999, 24, 751-762.	3.8	564
70	Apolipoprotein E genotype does not affect the age of onset of dementia in families with defined tau mutations. <i>Neuroscience Letters</i> , 1999, 260, 193-195.	1.0	27
71	Altered conformation of recombinant frontotemporal dementia-17 mutant tau proteins. <i>Neuroscience Letters</i> , 1999, 260, 153-156.	1.0	42
72	No genetic association between polymorphisms in the Tau gene and Alzheimer's disease in clinic or population based samples. <i>Neuroscience Letters</i> , 1999, 266, 193-196.	1.0	48
73	Exclusion of dominant mutations within the FTDP-17 locus on chromosome 17 for Parkinson's disease. <i>Neuroscience Letters</i> , 1999, 272, 140-142.	1.0	4
74	The tau gene in progressive supranuclear palsy: exclusion of mutations in coding exons and exon 10 splice sites, and identification of a new intronic variant of the disease-associated H1 haplotype in Italian cases. <i>Neuroscience Letters</i> , 1999, 274, 61-65.	1.0	26
75	Mutation screening of the tau gene in patients with early-onset Alzheimer's disease. <i>Neuroscience Letters</i> , 1999, 277, 137-139.	1.0	43

#	ARTICLE	IF	CITATIONS
76	Tau protein and the paired helical filament of Alzheimer's disease. Brain Research Bulletin, 1999, 50, 469-470.	1.4	20
77	Mutations in the Tau gene cause frontotemporal dementia. Brain Research Bulletin, 1999, 50, 471-472.	1.4	8
78	Phylogenetic diversity of the expression of the microtubule-associated protein tau: implications for neurodegenerative disorders. Molecular Brain Research, 1999, 68, 119-128.	2.5	90
79	FTDP-17 mutations N279K and S305N in tau produce increased splicing of exon 10. FEBS Letters, 1999, 443, 93-96.	1.3	188
80	Polymerization of tau peptides into fibrillar structures. The effect of FTDP-17 mutations. FEBS Letters, 1999, 446, 199-202.	1.3	113
81	Mutations in tau reduce its microtubule binding properties in intact cells and affect its phosphorylation. FEBS Letters, 1999, 446, 228-232.	1.3	188
82	Effects of frontotemporal dementia FTDP-17 mutations on heparin-induced assembly of tau filaments. FEBS Letters, 1999, 450, 306-311.	1.3	231
83	Assembly of paired helical filaments from mouse tau: implications for the neurofibrillary pathology in transgenic mouse models for Alzheimer's disease. FEBS Letters, 1999, 451, 39-44.	1.3	81
84	FTDP-17 tau mutations decrease the susceptibility of tau to calpain I digestion. FEBS Letters, 1999, 461, 91-95.	1.3	45
85	Pathways to Primary Neurodegenerative Disease. Mayo Clinic Proceedings, 1999, 74, 835-837.	1.4	22
86	Filamentous nerve cell inclusions in neurodegenerative diseases: tauopathies and alpha-synucleinopathies. Philosophical Transactions of the Royal Society B: Biological Sciences, 1999, 354, 1101-1118.	1.8	165
87	New order from neurological disorders. Nature, 1999, 399, A3-A5.	13.7	67
88	The Tauopathies. American Journal of Pathology, 1999, 154, 1-6.	1.9	54
89	Transgenic Expression of the Shortest Human Tau Affects Its Compartmentalization and Its Phosphorylation as in the Pretangle Stage of Alzheimer's Disease. American Journal of Pathology, 1999, 154, 255-270.	1.9	200
90	Stable Expression in Chinese Hamster Ovary Cells of Mutated Tau Genes Causing Frontotemporal Dementia and Parkinsonism Linked to Chromosome 17 (FTDP-17). American Journal of Pathology, 1999, 154, 1649-1656.	1.9	82
91	Tau Pathology Generated by Overexpression of Tau. American Journal of Pathology, 1999, 155, 1781-1785.	1.9	14
92	Prominent Axonopathy in the Brain and Spinal Cord of Transgenic Mice Overexpressing Four-Repeat Human tau Protein. American Journal of Pathology, 1999, 155, 2153-2165.	1.9	379
93	The Guam Cycad Toxin Methylazoxymethanol Damages Neuronal DNA and Modulates Tau mRNA Expression and Excitotoxicity. Experimental Neurology, 1999, 155, 11-21.	2.0	64

#	ARTICLE	IF	CITATIONS
94	Construction of a Detailed Physical and Transcript Map of the FTDP-17 Candidate Region on Chromosome 17q21. <i>Genomics</i> , 1999, 60, 129-136.	1.3	7
95	Role of Oxidative Stress in Frontotemporal Dementia. <i>Dementia and Geriatric Cognitive Disorders</i> , 1999, 10, 85-87.	0.7	30
96	Chapter 1 Genetic Contributions to the Pathogenesis of Alzheimer's Disease. <i>Advances in Cell Aging and Gerontology</i> , 1999, , 1-31.	0.1	1
97	A mutation in the microtubule-associated protein tau in pallido-nigro-luysian degeneration. <i>Neurology</i> , 1999, 53, 864-864.	1.5	97
100	Neuronal Death in Alzheimer's Disease.. <i>Internal Medicine</i> , 2000, 39, 328-330.	0.3	4
101	Linkage of Familial Amyotrophic Lateral Sclerosis With Frontotemporal Dementia to Chromosome 9q21-q22. <i>JAMA - Journal of the American Medical Association</i> , 2000, 284, 1664.	3.8	281
102	<i><i>Tau</i></i> Gene Mutation K257T Causes a Tauopathy Similar to Pick's Disease. <i>Journal of Neuropathology and Experimental Neurology</i> , 2000, 59, 990-1001.	0.9	145
103	Pro-apoptotic effects of tau mutations in chromosome 17 frontotemporal dementia and parkinsonism. <i>NeuroReport</i> , 2000, 11, 57-59.	0.6	28
104	Tau pathology: a marker of neurodegenerative disorders. <i>Current Opinion in Neurology</i> , 2000, 13, 371-376.	1.8	113
105	Neuropathology of amyotrophic lateral sclerosis with extra-motor system degeneration: Characteristics and differences in the molecular pathology between ALS with dementia and Guamanian ALS. <i>Amyotrophic Lateral Sclerosis and Other Motor Neuron Disorders: Official Publication of the World Federation of Neurology, Research Group on Motor Neuron Diseases</i> , 2000, 1, 87-104.	1.4	17
106	Missense point mutations of tau to segregate with FTDP-17 exhibit site-specific effects on microtubule structure in COS cells: A novel action of R406W mutation. , 2000, 60, 380-387.		33
107	Significant association between the tau gene A0/A0 genotype and Parkinson's disease. <i>Annals of Neurology</i> , 2000, 47, 242-245.	2.8	129
108	Corticobasal degeneration shares a common genetic background with progressive supranuclear palsy. <i>Annals of Neurology</i> , 2000, 47, 374-377.	2.8	216
109	A novel mutation at position +12 in the intron following Exon 10 of the tau gene in familial frontotemporal dementia (FTD-Kumamoto). <i>Annals of Neurology</i> , 2000, 47, 422-429.	2.8	109
110	Expression profile of transcripts in Alzheimer's disease tangle-bearing CA1 neurons. <i>Annals of Neurology</i> , 2000, 48, 77-87.	2.8	310
111	Frontotemporal dementia with novel tau pathology and a Glu342Valtau mutation. <i>Annals of Neurology</i> , 2000, 48, 850-858.	2.8	97
112	Pick's disease is associated with mutations in the tau gene. <i>Annals of Neurology</i> , 2000, 48, 859-867.	2.8	131
113	A novel tau mutation (N296N) in familial dementia with swollen achromatic neurons and corticobasal inclusion bodies. <i>Annals of Neurology</i> , 2000, 48, 939-943.	2.8	136

#	ARTICLE	IF	CITATIONS
114	Research goals in progressive supranuclear palsy. <i>Movement Disorders</i> , 2000, 15, 446-458.	2.2	29
115	The solution structure of the C-terminal segment of tau protein. <i>Journal of Peptide Science</i> , 2000, 6, 550-559.	0.8	17
116	Untangling Alzheimer's disease from fibrous lesions of neurofibrillary tangles and senile plaques. <i>Neuropathology</i> , 2000, 20, 55-60.	0.7	9
117	A new case of frontotemporal dementia and parkinsonism resulting from an intron 10 Δ f+3-splice site mutation in the tau gene: clinical and pathological features. <i>Neuropathology and Applied Neurobiology</i> , 2000, 26, 368-378.	1.8	37
118	The molecular genetics of the tauopathies. <i>Experimental Gerontology</i> , 2000, 35, 461-471.	1.2	49
119	Animal models of Alzheimer's disease and evaluation of anti-dementia drugs. , 2000, 88, 93-113.		155
120	Missense tau mutations identified in FTDP-17 have a small effect on tau's microtubule interactions. <i>Brain Research</i> , 2000, 853, 5-14.	1.1	78
121	Progress in the clinical and molecular genetics of familial parkinsonism. <i>Neurogenetics</i> , 2000, 2, 207-218.	0.7	36
122	Familial frontotemporal dementia with ubiquitin inclusion bodies and without motor neuron disease. <i>Acta Neuropathologica</i> , 2000, 100, 421-426.	3.9	32
123	Axonopathy and amyotrophy in mice transgenic for human four-repeat tau protein. <i>Acta Neuropathologica</i> , 2000, 99, 469-481.	3.9	344
124	A case of frontotemporal dementia with tau P301L mutation in the Far East. <i>Journal of Neurology</i> , 2000, 247, 705-707.	1.8	12
125	Assembly of tau protein into Alzheimer paired helical filaments depends on a local sequence motif (306VQIVYK311) forming beta structure. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2000, 97, 5129-5134.	3.3	909
126	Progressive supranuclear palsy pathology caused by a novel silent mutation in exon 10 of the tau gene. <i>Brain</i> , 2000, 123, 880-893.	3.7	277
127	Determinants of 4-Repeat Tau Expression. <i>Journal of Biological Chemistry</i> , 2000, 275, 17700-17709.	1.6	123
128	Aberrant Splicing of tau Pre-mRNA Caused by Intronic Mutations Associated with the Inherited Dementia Frontotemporal Dementia with Parkinsonism Linked to Chromosome 17. <i>Molecular and Cellular Biology</i> , 2000, 20, 4036-4048.	1.1	121
130	A Japanese patient with frontotemporal dementia and parkinsonism by a tau P301S mutation. <i>Neurology</i> , 2000, 55, 1224-1227.	1.5	39
131	Dementia with prominent frontotemporal features associated with L113P presenilin 1 mutation. <i>Neurology</i> , 2000, 55, 1577-1579.	1.5	126
132	Two brothers with frontotemporal dementia and parkinsonism with an N279K mutation of the tau gene. <i>Neurology</i> , 2000, 54, 1787-1795.	1.5	71

#	ARTICLE	IF	CITATIONS
133	Case 11-2000. New England Journal of Medicine, 2000, 342, 1110-1117.	13.9	10
134	Tau mutations in familial frontotemporal dementia. Brain, 2000, 123, 857-859.	3.7	48
135	Mutation-dependent aggregation of tau protein and its selective depletion from the soluble fraction in brain of P301L FTDP-17 patients. Human Molecular Genetics, 2000, 9, 3075-3082.	1.4	57
136	Distinct FTDP-17 Missense Mutations in Tau Produce Tau Aggregates and Other Pathological Phenotypes in Transfected CHO Cells. Molecular Biology of the Cell, 2000, 11, 4093-4104.	0.9	119
137	Two brothers with frontotemporal dementia and parkinsonism with an N279K mutation of the tau gene. Neurology, 2000, 55, 1939-1942.	1.5	41
138	Familial frontotemporal dementia with ubiquitin-positive, tau-negative inclusions. Neurology, 2000, 54, 818-827.	1.5	144
139	Untangling tau-related dementia. Human Molecular Genetics, 2000, 9, 979-986.	1.4	101
140	An extended 5â€²- <i>tau</i> susceptibility haplotype in progressive supranuclear palsy. Neurology, 2000, 55, 1364-1367.	1.5	54
141	Search for a Mutation in the tau Gene in a Swiss Family with Frontotemporal Dementia. Experimental Neurology, 2000, 161, 330-335.	2.0	14
142	Amyloid-Î² Injection in Rat Amygdala Alters Tau Protein but Not mRNA Expression. Experimental Neurology, 2000, 162, 158-170.	2.0	18
143	Apolipoprotein E Î¼4 Allele Has No Effect on Age at Onset or Duration of Disease in Cases of Frontotemporal Dementia with Pick- or Microvacuolar-Type Histology. Experimental Neurology, 2000, 163, 452-456.	2.0	45
144	Single-Step Conversion of P1 and P1 Artificial Chromosome Clones into Yeast Artificial Chromosomes. Genomics, 2000, 68, 106-110.	1.3	6
145	Abnormal Tau-Containing Filaments in Neurodegenerative Diseases. Journal of Structural Biology, 2000, 130, 271-279.	1.3	170
146	Characterization of Pathology in Transgenic Mice Over-Expressing Human Genomic and cDNA Tau Transgenes. Neurobiology of Disease, 2000, 7, 87-98.	2.1	284
147	Tau protein isoforms, phosphorylation and role in neurodegenerative disorders11These authors contributed equally to this work.. Brain Research Reviews, 2000, 33, 95-130.	9.1	1,743
148	Wnt signaling function in Alzheimerâ€™s disease. Brain Research Reviews, 2000, 33, 1-12.	9.1	275
149	Tau polymorphisms are not associated with Alzheimer's disease. Neuroscience Letters, 2000, 284, 77-80.	1.0	36
150	No association between TAU haplotype and Alzheimer's disease in population or clinic based series or in familial disease. Neuroscience Letters, 2000, 285, 147-149.	1.0	40

#	ARTICLE	IF	CITATIONS
151	Casein kinase 1 delta is associated with pathological accumulation of tau in several neurodegenerative diseases. <i>Neurobiology of Aging</i> , 2000, 21, 503-510.	1.5	136
152	Quantitative neurohistological features of frontotemporal degeneration. <i>Neurobiology of Aging</i> , 2000, 21, 913-919.	1.5	70
153	Mitotic activation: a convergent mechanism for a cohort of neurodegenerative diseases. <i>Neurobiology of Aging</i> , 2000, 21, 815-828.	1.5	183
154	New insights into genetic and molecular mechanisms of brain degeneration in tauopathies. <i>Journal of Chemical Neuroanatomy</i> , 2000, 20, 225-244.	1.0	46
155	Tau mutations in frontotemporal dementia FTDP-17 and their relevance for Alzheimer's disease. <i>Biochimica Et Biophysica Acta - Molecular Basis of Disease</i> , 2000, 1502, 110-121.	1.8	127
156	Structure of tau protein and assembly into paired helical filaments. <i>Biochimica Et Biophysica Acta - Molecular Basis of Disease</i> , 2000, 1502, 122-132.	1.8	130
157	Tau aggregation into fibrillar polymers: tauopathies. <i>FEBS Letters</i> , 2000, 476, 89-92.	1.3	77
158	The natural osmolyte trimethylamineN-oxide (TMAO) restores the ability of mutant tau to promote microtubule assembly. <i>FEBS Letters</i> , 2000, 484, 265-270.	1.3	42
159	FRONTOTEMPORAL DEMENTIA. <i>Neurologic Clinics</i> , 2000, 18, 979-992.	0.8	32
160	Familial frontotemporal dementia with a P301L tau mutation in Japan. <i>Journal of the Neurological Sciences</i> , 2000, 176, 57-64.	0.3	27
161	Neurodegenerative Tauopathies. <i>Annual Review of Neuroscience</i> , 2001, 24, 1121-1159.	5.0	2,416
162	Clinic-Based Cases with Frontotemporal Dementia Show Increased Cerebrospinal Fluid Tau and High Apolipoprotein E ϵ 4 Frequency, but No Tau Gene Mutations. <i>Experimental Neurology</i> , 2001, 168, 413-418.	2.0	70
163	Regulation of Alternative Splicing of Human Tau Exon 10 by Phosphorylation of Splicing Factors. <i>Molecular and Cellular Neurosciences</i> , 2001, 18, 80-90.	1.0	101
164	FTDP-17 Mutations in tau Transgenic Mice Provoke Lysosomal Abnormalities and Tau Filaments in Forebrain. <i>Molecular and Cellular Neurosciences</i> , 2001, 18, 702-714.	1.0	207
165	Formation of Filamentous Tau Aggregations in Transgenic Mice Expressing V337M Human Tau. <i>Neurobiology of Disease</i> , 2001, 8, 1036-1045.	2.1	136
166	Molecular Analysis of Mutant and Wild-Type Tau Deposited in the Brain Affected by the FTDP-17 R406W Mutation. <i>American Journal of Pathology</i> , 2001, 158, 373-379.	1.9	55
167	Structural Analysis of Pick's Disease-Derived and in Vitro-Assembled Tau Filaments. <i>American Journal of Pathology</i> , 2001, 158, 1481-1490.	1.9	53
168	Pathological glial tau accumulations in neurodegenerative disease: review and case report. <i>Neurochemistry International</i> , 2001, 39, 469-479.	1.9	39

#	ARTICLE	IF	CITATIONS
169	Tau proteins with frontotemporal dementia-17 mutations have both altered expression levels and phosphorylation profiles in differentiated neuroblastoma cells. <i>Neuroscience</i> , 2001, 108, 701-712.	1.1	26
170	Copper in disorders with neurological symptoms: Alzheimer's, Menkes, and Wilson diseases. <i>Brain Research Bulletin</i> , 2001, 55, 175-185.	1.4	426
171	The extended haplotype of the microtubule associated protein tau gene is not associated with Pick's disease. <i>Neuroscience Letters</i> , 2001, 299, 156-158.	1.0	35
172	The Apolipoprotein E genotype in patients affected by syndromes with focal cortical atrophy. <i>Neuroscience Letters</i> , 2001, 303, 87-90.	1.0	13
173	Tau accumulation in a patient with pallidonigroluysian atrophy. <i>Neuroscience Letters</i> , 2001, 309, 89-92.	1.0	14
174	Strong association of a novel Tau promoter haplotype in progressive supranuclear palsy. <i>Neuroscience Letters</i> , 2001, 311, 145-148.	1.0	49
175	Tau and transgenic animal models. <i>Brain Research Reviews</i> , 2001, 35, 266-286.	9.1	142
176	Parkinson disease: etiology, pathogenesis and future of gene therapy. <i>Neuroscience Research</i> , 2001, 41, 5-12.	1.0	100
177	Familial amyotrophic lateral sclerosis and parkinsonism-dementia complex of the Kii peninsula of Japan: Clinical and neuropathological study and tau analysis. <i>Annals of Neurology</i> , 2001, 49, 501-511.	2.8	108
178	Regulation of microtubule-associated proteins. <i>International Review of Cytology</i> , 2001, 210, 163-226.	6.2	175
179	Analysis of tauopathies with transgenic mice. <i>Trends in Molecular Medicine</i> , 2001, 7, 467-470.	3.5	92
180	The significance of tau and β -synuclein inclusions in neurodegenerative diseases. <i>Current Opinion in Genetics and Development</i> , 2001, 11, 343-351.	1.5	89
181	Effects of FTDP-17 mutations on the in vitro phosphorylation of tau by glycogen synthase kinase 3 β identified by mass spectrometry demonstrate certain mutations exert long-range conformational changes. <i>FEBS Letters</i> , 2001, 493, 40-44.	1.3	34
182	An overview of common non-alzheimer dementias. <i>Clinics in Geriatric Medicine</i> , 2001, 17, 281-301.	1.0	29
183	Etiology, Genetics, and Pathogenesis of Alzheimer's Disease. , 2001, , 333-348.		0
184	Frontotemporal Dementias: From Classification Problems to Pathogenetic Uncertainties. , 2001, , 145-154.		0
185	The genetic causes of neurodegenerative diseases. <i>Journal of Alzheimer's Disease</i> , 2001, 3, 109-116.	1.2	19
186	Prion disease resembling frontotemporal dementia and parkinsonism linked to chromosome 17. <i>Arquivos De Neuro-Psiquiatria</i> , 2001, 59, 161-164.	0.3	26

#	ARTICLE	IF	CITATIONS
187	Tau Phosphorylation. , 2001, , 315-332.		5
188	Attenuated Neurodegenerative Disease Phenotype in Tau Transgenic Mouse Lacking Neurofilaments. <i>Journal of Neuroscience</i> , 2001, 21, 6026-6035.	1.7	71
189	Lead content of brain tissue in diffuse neurofibrillary tangles with calcification (DNFC): the possibility of lead neurotoxicity. <i>NeuroReport</i> , 2001, 12, 3887-3890.	0.6	36
190	Compartmentalized tau hyperphosphorylation and increased levels of kinases in transgenic mice. <i>NeuroReport</i> , 2001, 12, 2007-2016.	0.6	42
191	Selective Deposition of Mutant Tau in the FTDP-17 Brain Affected by the P301L Mutation. <i>Journal of Neuropathology and Experimental Neurology</i> , 2001, 60, 872-884.	0.9	47
192	Transgenic mouse models of tauopathies: Prospects for animal models of Pick's disease. <i>Neurology</i> , 2001, 56, S26-30.	1.5	22
193	Frontotemporal Lobar Degeneration. <i>Gerontology</i> , 2001, 47, 1-8.	1.4	23
194	Familial frontotemporal dementia with ubiquitin-positive inclusions is linked to chromosome 17q21-22. <i>Brain</i> , 2001, 124, 1948-1957.	3.7	143
195	Impact of DNA Testing for Early-Onset Familial Alzheimer Disease and Frontotemporal Dementia. <i>Archives of Neurology</i> , 2001, 58, 1828.	4.9	116
196	Frontal Lobe Dementia With Novel Tauopathy: Sporadic Multiple System Tauopathy With Dementia. <i>Journal of Neuropathology and Experimental Neurology</i> , 2001, 60, 328-341.	0.9	83
197	Genetic Analysis in Patients with Familial and Sporadic Frontotemporal Dementia: Two Tau Mutations in Only Familial Cases and No Association with Apolipoprotein μ 4. <i>Dementia and Geriatric Cognitive Disorders</i> , 2001, 12, 387-392.	0.7	25
198	TAU as a Susceptibility Gene for Amyotrophic Lateral Sclerosis-Parkinsonism Dementia Complex of Guam. <i>Archives of Neurology</i> , 2001, 58, 1871.	4.9	73
199	A genomic sequence analysis of the mouse and human microtubule-associated protein tau. <i>Mammalian Genome</i> , 2001, 12, 700-712.	1.0	59
201	Familial frontotemporal dementia and parkinsonism with a novel N296H mutation in exon 10 of the tau gene and a widespread tau accumulation in the glial cells. <i>Acta Neuropathologica</i> , 2001, 102, 285-292.	3.9	88
202	Complex Regulation of Tau Exon 10, Whose Missplicing Causes Frontotemporal Dementia. <i>Journal of Neurochemistry</i> , 2001, 74, 490-500.	2.1	80
203	Frontal Lobe Dysfunction in Progressive Supranuclear Palsy. <i>Journal of Neurochemistry</i> , 2001, 74, 878-881.	2.1	95
204	Creutzfeldt-Jakob disease segregating in a three generation Danish family. <i>Acta Neurologica Scandinavica</i> , 2001, 103, 139-147.	1.0	2
205	Behaviour in frontotemporal dementia, Alzheimer's disease and vascular dementia. <i>Acta Neurologica Scandinavica</i> , 2001, 103, 367-378.	1.0	244

#	ARTICLE	IF	CITATIONS
206	Oligodendroglial tau filament formation in transgenic mice expressing G272V tau. <i>European Journal of Neuroscience</i> , 2001, 13, 2131-2140.	1.2	96
207	Frontotemporal dementia and Parkinsonism linked to chromosome 17 (FTDP-17): PPND family. A longitudinal videotape demonstration. <i>Movement Disorders</i> , 2001, 16, 756-760.	2.2	8
208	Dementia and neurodevelopmental predisposition: Cognitive dysfunction in presymptomatic subjects precedes dementia by decades in frontotemporal dementia. <i>Annals of Neurology</i> , 2001, 50, 741-746.	2.8	112
209	Familial frontotemporal dementia and parkinsonism with a novel mutation at an intron 10+11-splice site in the tau gene. <i>Annals of Neurology</i> , 2001, 50, 117-120.	2.8	59
210	Pick's disease associated with the novel Tau gene mutation K369I. <i>Annals of Neurology</i> , 2001, 50, 503-513.	2.8	128
211	The case of the missing Tau, or, why didn't the mRNA bark?. <i>Annals of Neurology</i> , 2001, 49, 144-145.	2.8	3
212	Loss of brain tau defines novel sporadic and familial tauopathies with frontotemporal dementia. <i>Annals of Neurology</i> , 2001, 49, 165-175.	2.8	159
213	The splice of life: Alternative splicing and neurological disease. <i>Nature Reviews Neuroscience</i> , 2001, 2, 43-50.	4.9	139
214	Going new places using an old MAP: tau, microtubules and human neurodegenerative disease. <i>Current Opinion in Cell Biology</i> , 2001, 13, 41-48.	2.6	218
215	Genetic dissection of neurodegenerative disease. <i>Clinical Neuroscience Research</i> , 2001, 1, 134-141.	0.8	8
216	Tracking the decline in cerebral glucose metabolism in persons and laboratory animals at genetic risk for Alzheimer's disease. <i>Clinical Neuroscience Research</i> , 2001, 1, 194-206.	0.8	26
217	Tau Mutations—Center Tent or Sideshow?. <i>Archives of Neurology</i> , 2001, 58, 351-2.	4.9	3
218	Association of Single-Nucleotide Polymorphisms of the Tau Gene With Late-Onset Parkinson Disease. <i>JAMA - Journal of the American Medical Association</i> , 2001, 286, 2245.	3.8	171
219	Functional Differences of Tau Isoforms Containing 3 or 4 C-terminal Repeat Regions and the Influence of Oxidative Stress. <i>Journal of Biological Chemistry</i> , 2001, 276, 34288-34297.	1.6	20
220	Analysis of α -synuclein, parkin, tau, and UCH-L1 in a Japanese Family with Autosomal Dominant Parkinsonism. <i>European Neurology</i> , 2001, 46, 20-24.	0.6	13
221	Learning and Memory in Transgenic Mice Modeling Alzheimer's Disease. <i>Learning and Memory</i> , 2001, 8, 301-308.	0.5	205
222	Interaction of Tau Isoforms with Alzheimer's Disease Abnormally Hyperphosphorylated Tau and in Vitro Phosphorylation into the Disease-like Protein. <i>Journal of Biological Chemistry</i> , 2001, 276, 37967-37973.	1.6	131
223	Frequency of Tau Gene Mutations in Familial and Sporadic Cases of Non-Alzheimer Dementia. <i>Archives of Neurology</i> , 2001, 58, 383-7.	4.9	143

#	ARTICLE	IF	CITATIONS
224	Corticobasal degeneration and progressive supranuclear palsy share a common tau haplotype. <i>Neurology</i> , 2001, 56, 1702-1706.	1.5	392
225	BIOMEDICINE: Enhanced: Tauists and baptists United--Well Almost!. <i>Science</i> , 2001, 293, 1446-1447.	6.0	49
226	Ethical Principles and Pitfalls of Genetic Testing for Dementia. <i>Journal of Geriatric Psychiatry and Neurology</i> , 2001, 14, 213-221.	1.2	17
227	Tau and Parkinson Disease. <i>JAMA - Journal of the American Medical Association</i> , 2001, 286, 2324.	3.8	26
228	Complete Genomic Screen in Parkinson Disease. <i>JAMA - Journal of the American Medical Association</i> , 2001, 286, 2239.	3.8	257
229	Missense and splice site mutations in tau associated with FTDP-17: Multiple pathogenic mechanisms. <i>Neurology</i> , 2001, 56, S21-5.	1.5	116
230	From genetics to pathology: tau and "synuclein assemblies in neurodegenerative diseases. <i>Philosophical Transactions of the Royal Society B: Biological Sciences</i> , 2001, 356, 213-227.	1.8	58
231	Senile Dementia of the Neurofibrillary Tangle Type: A Comparison with Alzheimer's Disease. <i>Dementia and Geriatric Cognitive Disorders</i> , 2001, 12, 117-126.	0.7	32
232	The Genetic and Pathological Classification of Familial Frontotemporal Dementia. <i>Archives of Neurology</i> , 2001, 58, 1813.	4.9	114
233	In Vitro Assembly of Alzheimer-like Filaments. <i>Journal of Biological Chemistry</i> , 2002, 277, 34755-34759.	1.6	16
234	tau Exon 10 Expression Involves a Bipartite Intron 10 Regulatory Sequence and Weak 5' and 3' Splice Sites. <i>Journal of Biological Chemistry</i> , 2002, 277, 26587-26599.	1.6	78
235	Gene finding in genetically isolated populations. <i>Human Molecular Genetics</i> , 2002, 11, 2507-2515.	1.4	102
236	Sequence analysis of tau in familial and sporadic progressive supranuclear palsy. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , 2002, 72, 388-390.	0.9	17
237	Guadeloupean parkinsonism: a cluster of progressive supranuclear palsy-like tauopathy. <i>Brain</i> , 2002, 125, 801-811.	3.7	157
238	Neuropathologic variation in frontotemporal dementia due to the intronic τ 10 ⁺¹⁶ mutation. <i>Neurology</i> , 2002, 58, 1169-1175.	1.5	49
239	Chromosome 3 linked frontotemporal dementia (FTD-3). <i>Neurology</i> , 2002, 59, 1585-1594.	1.5	110
240	Functional Characterization of FTDP-17 tau Gene Mutations through Their Effects on Xenopus Oocyte Maturation. <i>Journal of Biological Chemistry</i> , 2002, 277, 9199-9205.	1.6	44
241	Progressive supranuclear palsy: clinical and genetic aspects. <i>Current Opinion in Neurology</i> , 2002, 15, 429-437.	1.8	20

#	ARTICLE	IF	CITATIONS
242	New developments in frontotemporal dementia and parkinsonism linked to chromosome 17. <i>Current Opinion in Neurology</i> , 2002, 15, 423-438.	1.8	38
243	Frontotemporal dementia: A review. <i>Journal of the International Neuropsychological Society</i> , 2002, 8, 566-583.	1.2	158
244	Association Between the Extended tau Haplotype and Frontotemporal Dementia. <i>Archives of Neurology</i> , 2002, 59, 935.	4.9	100
245	tau Assembly in Inducible Transfectants Expressing Wild-Type or FTDP-17 tau. <i>American Journal of Pathology</i> , 2002, 161, 1711-1722.	1.9	64
246	P301L tauopathy. <i>Journal of the Neurological Sciences</i> , 2002, 200, 85-93.	0.3	24
247	The Amyloid Hypothesis of Alzheimer's Disease: Progress and Problems on the Road to Therapeutics. <i>Science</i> , 2002, 297, 353-356.	6.0	12,113
248	Genetics of dementia. <i>Medical Clinics of North America</i> , 2002, 86, 591-614.	1.1	22
249	Inherited dementias. <i>Neurologic Clinics</i> , 2002, 20, 779-808.	0.8	12
250	Tau filament formation and associative memory deficit in aged mice expressing mutant (R406W) human tau. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2002, 99, 13896-13901.	3.3	254
251	The prevalence of frontotemporal dementia. <i>Neurology</i> , 2002, 58, 1615-1621.	1.5	1,057
252	Phosphorylation of microtubule-associated protein tau by stress-activated protein kinases in intact cells. <i>FEBS Letters</i> , 2002, 515, 151-154.	1.3	65
253	Transgenic Mouse Model of Tauopathies with Glial Pathology and Nervous System Degeneration. <i>Neuron</i> , 2002, 35, 433-446.	3.8	142
254	Tau gene mutations: dissecting the pathogenesis of FTDP-17. <i>Trends in Molecular Medicine</i> , 2002, 8, 555-562.	3.5	174
255	A family with a tau P301L mutation presenting with parkinsonism. <i>Parkinsonism and Related Disorders</i> , 2002, 9, 121-123.	1.1	12
256	Tau neurotoxicity without the lesions: a fly challenges a tangled web. <i>Trends in Neurosciences</i> , 2002, 25, 327-329.	4.2	22
257	Effects on splicing and protein function of three mutations in codon N296 of tau in vitro. <i>Neuroscience Letters</i> , 2002, 323, 33-36.	1.0	54
258	A clinical and neuropathological study of an unusual case of sporadic tauopathy. A variant of corticobasal degeneration?. <i>Neuroscience Letters</i> , 2002, 330, 84-88.	1.0	16
259	The tau locus is not significantly associated with pathologically confirmed sporadic Parkinson's disease. <i>Neuroscience Letters</i> , 2002, 330, 201-203.	1.0	39

#	ARTICLE	IF	CITATIONS
260	The role of tau in Alzheimer's disease. Medical Clinics of North America, 2002, 86, 615-627.	1.1	62
261	Frontotemporal dementia. Medical Clinics of North America, 2002, 86, 501-518.	1.1	29
262	Neurodegeneration with Tau Accumulation in a Transgenic Mouse Expressing V337M Human Tau. Journal of Neuroscience, 2002, 22, 133-141.	1.7	232
263	The Slow Axonal Transport of the Microtubule-Associated Protein Tau and the Transport Rates of Different Isoforms and Mutants in Cultured Neurons. Journal of Neuroscience, 2002, 22, 6394-6400.	1.7	69
264	Neurofibrillary pathology leads to synaptic loss and not the other way around in Alzheimer disease. Journal of Alzheimer's Disease, 2002, 4, 235-238.	1.2	35
265	Tau, where are we now?. Journal of Alzheimer's Disease, 2002, 4, 375-398.	1.2	83
266	Expression of a Variant Form of the Glutamate Transporter GLT1 in Neuronal Cultures and in Neurons and Astrocytes in the Rat Brain. Journal of Neuroscience, 2002, 22, 2142-2152.	1.7	193
267	Abundant Tau Filaments and Nonapoptotic Neurodegeneration in Transgenic Mice Expressing Human P301S Tau Protein. Journal of Neuroscience, 2002, 22, 9340-9351.	1.7	643
268	Clinical features of frontotemporal dementia due to the intronic τ +16 mutation. Neurology, 2002, 58, 1161-1168.	1.5	85
269	Pathological, clinical and genetic heterogeneity in progressive supranuclear palsy. Brain, 2002, 125, 969-975.	3.7	80
270	Involvement of microtubule integrity in memory impairment caused by colchicine. Pharmacology Biochemistry and Behavior, 2002, 71, 119-138.	1.3	59
271	A new locus for Parkinson's disease (PARK8) maps to chromosome 12p11.2-q13.1. Annals of Neurology, 2002, 51, 296-301.	2.8	608
272	A novel tau mutation, S320F, causes a tauopathy with inclusions similar to those in Pick's disease. Annals of Neurology, 2002, 51, 373-376.	2.8	91
273	Late-onset frontotemporal dementia with a novel exon 1 (Arg5His) tau gene mutation. Annals of Neurology, 2002, 51, 525-530.	2.8	138
274	An R5L mutation in a subject with a progressive supranuclear palsy phenotype. Annals of Neurology, 2002, 52, 511-516.	2.8	193
275	Is the Saitohin gene involved in neurodegenerative diseases?. Annals of Neurology, 2002, 52, 829-832.	2.8	35
276	Alzheimer's disease: β -Amyloid protein and tau. Journal of Neuroscience Research, 2002, 70, 392-401.	1.3	98
277	Transgenic zebrafish model of neurodegeneration. Journal of Neuroscience Research, 2002, 70, 734-745.	1.3	97

#	ARTICLE	IF	CITATIONS
278	Further extension of the H1 haplotype associated with progressive supranuclear palsy. <i>Movement Disorders</i> , 2002, 17, 550-556.	2.2	61
279	Familial conformational diseases and dementias. <i>Human Mutation</i> , 2002, 20, 1-14.	1.1	51
280	Axonopathy, tau abnormalities, and dyskinesia, but no neurofibrillary tangles in p25-transgenic mice. <i>Journal of Comparative Neurology</i> , 2002, 446, 257-266.	0.9	99
281	Significance and mechanism of alzheimer neurofibrillary degeneration and therapeutic targets to inhibit this lesion. <i>Journal of Molecular Neuroscience</i> , 2002, 19, 95-99.	1.1	55
282	Functions and malfunctions of the tau proteins. <i>Cellular and Molecular Life Sciences</i> , 2002, 59, 1668-1680.	2.4	149
283	Contrasting genotypes of the tau gene in two phenotypically distinct patients with P301L mutation of frontotemporal dementia and parkinsonism linked to chromosome 17. <i>Journal of Neurology</i> , 2002, 249, 669-675.	1.8	19
284	A large Calabrian kindred segregating frontotemporal dementia. <i>Journal of Neurology</i> , 2002, 249, 911-922.	1.8	20
285	Functional effects of tau gene mutations DeltaN296 and N296H. <i>Journal of Neurochemistry</i> , 2002, 80, 548-551.	2.1	57
286	Potential novel targets for Alzheimer pharmacotherapy: I. Secretases. <i>Journal of Clinical Pharmacy and Therapeutics</i> , 2002, 27, 169-183.	0.7	24
287	Differential Assembly of Human Tau Isoforms in the Presence of Arachidonic Acid. <i>Journal of Neurochemistry</i> , 2002, 74, 1749-1757.	2.1	147
288	The FTDP-17-Linked Mutation R406W Abolishes the Interaction of Phosphorylated Tau with Microtubules. <i>Journal of Neurochemistry</i> , 2002, 74, 2583-2589.	2.1	53
289	Reduced Binding of Protein Phosphatase 2A to Tau Protein with Frontotemporal Dementia and Parkinsonism Linked to Chromosome 17 Mutations. <i>Journal of Neurochemistry</i> , 2002, 75, 2155-2162.	2.1	87
290	Assembly of tau in transgenic animals expressing P301L tau: alteration of phosphorylation and solubility. <i>Journal of Neurochemistry</i> , 2002, 83, 1498-1508.	2.1	122
291	Apolipoprotein E gene in frontotemporal dementia: an association study and meta-analysis. <i>European Journal of Human Genetics</i> , 2002, 10, 399-405.	1.4	87
292	Discovery of Compounds That Will Prevent Tau Pathology. <i>Journal of Molecular Neuroscience</i> , 2002, 19, 261-266.	1.1	13
293	Tau Function and Dysfunction in Neurons. <i>Molecular Neurobiology</i> , 2002, 25, 213-232.	1.9	54
294	Advances in the Cellular and Molecular Biology of the Beta-Amyloid Protein in Alzheimer 's Disease. <i>NeuroMolecular Medicine</i> , 2002, 1, 1-32.	1.8	181
295	The Solved and Unsolved Mysteries of the Genetics of Early-Onset Alzheimer 's Disease. <i>NeuroMolecular Medicine</i> , 2002, 2, 01-10.	1.8	75

#	ARTICLE	IF	CITATIONS
296	Tau and Axonopathy in Neurodegenerative Disorders. <i>NeuroMolecular Medicine</i> , 2002, 2, 131-150.	1.8	120
297	Alzheimer Neurofibrillary Degeneration: Therapeutic Targets and High-Throughput Assays. <i>Journal of Molecular Neuroscience</i> , 2003, 20, 425-430.	1.1	27
298	Tau Protein in Familial and Sporadic Diseases. <i>NeuroMolecular Medicine</i> , 2003, 4, 37-48.	1.8	35
299	Ultrastructural neuronal pathology in transgenic mice expressing mutant (P301L) human tau. <i>Journal of Neurocytology</i> , 2003, 32, 1091-1105.	1.6	115
300	Repeat motifs of tau bind to the insides of microtubules in the absence of taxol. <i>EMBO Journal</i> , 2003, 22, 70-77.	3.5	299
301	The L266V tau mutation is associated with frontotemporal dementia and Pick-like 3R and 4R tauopathy. <i>Acta Neuropathologica</i> , 2003, 106, 323-336.	3.9	84
302	Frontotemporal dementia and parkinsonism with the P301S tau gene mutation in a Jewish family. <i>Journal of Neurology</i> , 2003, 250, 733-740.	1.8	50
303	Phenotypic presentation of frontotemporal dementia with Parkinsonism-chromosome 17 type P301S in a patient of Jewish-Algerian origin. <i>Movement Disorders</i> , 2003, 18, 595-598.	2.2	13
304	Update on epidemiological aspects of progressive supranuclear palsy. <i>Movement Disorders</i> , 2003, 18, 43-50.	2.2	121
305	Extended investigation of tau and mutation screening of other candidate genes on chromosome 17q21 in a Swedish FTDP-17 family. <i>American Journal of Medical Genetics Part A</i> , 2003, 121B, 112-118.	2.4	17
306	International approaches to frontotemporal dementia diagnosis: From social cognition to neuropsychology. <i>Annals of Neurology</i> , 2003, 54, S7-S10.	2.8	32
307	Variable phenotypic expression and extensive tau pathology in two families with the noveltau mutation L315R. <i>Annals of Neurology</i> , 2003, 54, 573-581.	2.8	82
308	An English kindred with a novel recessive tauopathy and respiratory failure. <i>Annals of Neurology</i> , 2003, 54, 682-686.	2.8	62
309	Alteration in calcium channel properties is responsible for the neurotoxic action of a familial frontotemporal dementia tau mutation. <i>Journal of Neurochemistry</i> , 2003, 87, 427-436.	2.1	59
310	Nitration of Tau Protein Is Linked to Neurodegeneration in Tauopathies. <i>American Journal of Pathology</i> , 2003, 163, 1021-1031.	1.9	183
311	Filamentous Tau in Oligodendrocytes and Astrocytes of Transgenic Mice Expressing the Human Tau Isoform with the P301L Mutation. <i>American Journal of Pathology</i> , 2003, 162, 213-218.	1.9	95
312	Tau haplotype frequency in frontotemporal lobar degeneration and amyotrophic lateral sclerosis. <i>Experimental Neurology</i> , 2003, 181, 12-16.	2.0	36
313	A novel tau mutation in exon 9 (1260V) causes a four-repeat tauopathy. <i>Experimental Neurology</i> , 2003, 184, 131-140.	2.0	59

#	ARTICLE	IF	CITATIONS
314	An N-terminal fragment of ProSAAS (a granin-like neuroendocrine peptide precursor) is associated with tau inclusions in Pick's disease. <i>Biochemical and Biophysical Research Communications</i> , 2003, 308, 646-654.	1.0	26
315	Gene structure and alternative splicing of glycogen synthase kinase 3 beta (GSK-3 β) in neural and non-neural tissues. <i>Gene</i> , 2003, 302, 73-81.	1.0	47
316	Distinct functions of tau isoforms in Alzheimer's disease. <i>International Congress Series</i> , 2003, 1252, 347-354.	0.2	0
317	A role of P301L tau mutant in anti-apoptotic gene expression, cell cycle and apoptosis. <i>Molecular and Cellular Neurosciences</i> , 2003, 24, 367-379.	1.0	29
318	Tau Phosphorylation, Tangles, and Neurodegeneration. <i>Neuron</i> , 2003, 40, 457-460.	3.8	129
319	Tau and neurofilaments in a family with frontotemporal dementia unlinked to chromosome 17q21. <i>Neurobiology of Disease</i> , 2003, 12, 46-55.	2.1	21
320	β -Amyloid Induces Paired Helical Filament-like Tau Filaments in Tissue Culture. <i>Journal of Biological Chemistry</i> , 2003, 278, 40162-40168.	1.6	159
321	Alzheimer disease and other dementias. <i>Clinics in Geriatric Medicine</i> , 2003, 19, 763-776.	1.0	14
322	Allele-specific silencing of dominant disease genes. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2003, 100, 7195-7200.	3.3	363
323	Neurodegeneration and defective neurotransmission in a <i>Caenorhabditis elegans</i> model of tauopathy. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2003, 100, 9980-9985.	3.3	336
324	The Genetics of Adult-Onset Neuropsychiatric Disease: Complexities and Conundra?. <i>Science</i> , 2003, 302, 822-826.	6.0	160
325	Mutations in Tau Gene Exon 10 Associated with FTDP-17 Alter the Activity of an Exonic Splicing Enhancer to Interact with Tra2 β . <i>Journal of Biological Chemistry</i> , 2003, 278, 18997-19007.	1.6	102
326	Neurodegenerative tauopathy in the worm. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2003, 100, 9653-9655.	3.3	7
327	Mouse models of Alzheimer's disease: The long and filamentous road. <i>Neurological Research</i> , 2003, 25, 590-600.	0.6	49
328	Novel Tau Polymorphisms, Tau Haplotypes, and Splicing in Familial and Sporadic Frontotemporal Dementia. <i>Archives of Neurology</i> , 2003, 60, 698.	4.9	53
329	Tau Protein in Frontotemporal Dementia Linked to Chromosome 3 (FTD-3). <i>Journal of Neuropathology and Experimental Neurology</i> , 2003, 62, 878-882.	0.9	36
330	Biochemical and Ultrastructural Study of Neurofibrillary Tangles in Amyotrophic Lateral Sclerosis/Parkinsonism-Dementia Complex in the Kii Peninsula of Japan. <i>Journal of Neuropathology and Experimental Neurology</i> , 2003, 62, 791-798.	0.9	24
331	The neurobiology of the tauopathies. , 2003, , 245-261.		0

#	ARTICLE	IF	CITATIONS
332	Diagnosis and Treatment of Dementia. , 2003, , 311-325.		1
333	17q-Linked Frontotemporal Dementia—Amyotrophic Lateral Sclerosis Without Tau Mutations With Tau and I±-Synuclein Inclusions. Archives of Neurology, 2004, 61, 398.	4.9	71
334	Similar early clinical presentations in familial and non-familial frontotemporal dementia. Journal of Neurology, Neurosurgery and Psychiatry, 2004, 75, 1743-1745.	0.9	25
335	Targeting Alzheimer's disease genes with RNA interference: an efficient strategy for silencing mutant alleles. Nucleic Acids Research, 2004, 32, 661-668.	6.5	139
336	The Tau Gene Locus and Frontotemporal Dementia. Dementia and Geriatric Cognitive Disorders, 2004, 17, 258-260.	0.7	9
337	Phenotypic Variation in Frontotemporal Dementia and Parkinsonism Linked to Chromosome 17. Dementia and Geriatric Cognitive Disorders, 2004, 17, 261-264.	0.7	21
338	Myotonic dystrophy type 1 is associated with nuclear foci of mutant RNA, sequestration of muscleblind proteins and deregulated alternative splicing in neurons. Human Molecular Genetics, 2004, 13, 3079-3088.	1.4	471
339	Clinical and Molecular Aspects of Frontotemporal Dementia. Neurodegenerative Diseases, 2004, 1, 218-224.	0.8	7
340	Animal models of tau phosphorylation and tauopathy — what have they taught us?. Advances in Cell Aging and Gerontology, 2004, 16, 153-175.	0.1	0
341	A non-DM1, non-DM2 multisystem myotonic disorder with frontotemporal dementia: phenotype and suggestive mapping of the DM3 locus to chromosome 15q21-24. Brain, 2004, 127, 1979-1992.	3.7	38
342	Gem GTPase and Tau. Journal of Biological Chemistry, 2004, 279, 27272-27277.	1.6	33
343	Mutant (R406W) Human Tau Is Hyperphosphorylated and Does Not Efficiently Bind Microtubules in a Neuronal Cortical Cell Model. Journal of Biological Chemistry, 2004, 279, 7893-7900.	1.6	45
344	Glycogen Synthase Kinase-3 Plays a Crucial Role in Tau Exon 10 Splicing and Intranuclear Distribution of SC35. Journal of Biological Chemistry, 2004, 279, 3801-3806.	1.6	122
345	Promotion of Hyperphosphorylation by Frontotemporal Dementia Tau Mutations. Journal of Biological Chemistry, 2004, 279, 34873-34881.	1.6	251
346	Retarded Axonal Transport of R406W Mutant Tau in Transgenic Mice with a Neurodegenerative Tauopathy. Journal of Neuroscience, 2004, 24, 4657-4667.	1.7	169
347	A minimal length between tau exon 10 and 11 is required for correct splicing of exon 10. Journal of Neurochemistry, 2004, 90, 164-172.	2.1	61
348	Phosphorylation of microtubule-associated protein tau by isoforms of c-Jun N-terminal kinase (JNK). Journal of Neurochemistry, 2004, 90, 352-358.	2.1	149
349	New V272A presenilin 1 mutation with very early onset subcortical dementia and parkinsonism. European Journal of Neurology, 2004, 11, 663-669.	1.7	51

#	ARTICLE	IF	CITATIONS
350	Cell biology of protein misfolding: The examples of Alzheimer's and Parkinson's diseases. <i>Nature Cell Biology</i> , 2004, 6, 1054-1061.	4.6	775
351	Neurodegenerative diseases: a decade of discoveries paves the way for therapeutic breakthroughs. <i>Nature Medicine</i> , 2004, 10, 1055-1063.	15.2	624
352	GSK3 inhibitors: development and therapeutic potential. <i>Nature Reviews Drug Discovery</i> , 2004, 3, 479-487.	21.5	696
353	Transgenic animal models of Alzheimer's disease and related disorders: histopathology, behavior and therapy. <i>Molecular Psychiatry</i> , 2004, 9, 664-683.	4.1	248
354	Frontotemporal degenerative dementias. <i>Clinical Neuroscience Research</i> , 2004, 3, 449-460.	0.8	3
355	Effects of Î±-tocopherol on an animal model of tauopathies. <i>Free Radical Biology and Medicine</i> , 2004, 37, 176-186.	1.3	92
356	Microglia as a Potential Bridge between the Amyloid A-Peptide and Tau. <i>Annals of the New York Academy of Sciences</i> , 2004, 1035, 85-103.	1.8	140
357	Frequency of tau mutations in familial and sporadic frontotemporal dementia and other tauopathies. <i>Journal of Neurology</i> , 2004, 251, 1098-104.	1.8	43
358	The cytoskeleton in neurodegenerative diseases. <i>Journal of Pathology</i> , 2004, 204, 438-449.	2.1	156
359	Evidence of a founder effect in families with frontotemporal dementia that harbor the tau +16 splice mutation. <i>American Journal of Medical Genetics Part A</i> , 2004, 125B, 79-82.	2.4	24
360	The role of tau (MAPT) in frontotemporal dementia and related tauopathies. <i>Human Mutation</i> , 2004, 24, 277-295.	1.1	323
361	Reference genes identified in SH-SY5Y cells using custom-made gene arrays with validation by quantitative polymerase chain reaction. <i>Analytical Biochemistry</i> , 2004, 335, 30-41.	1.1	73
362	Purification of Recombinant Tau Protein and Preparation of Alzheimer-Paired Helical Filaments In Vitro. , 2005, 299, 035-052.		149
363	The evolving role of genomics in shaping care for persons with dementia. <i>Nursing Clinics of North America</i> , 2004, 39, 581-592.	0.7	5
364	The neuropsychiatry of Parkinson's disease and related disorders. <i>Psychiatric Clinics of North America</i> , 2004, 27, 801-825.	0.7	87
365	P3-228 Chip and HSP70 regulate tau ubiquitination, degradation and aggregation. <i>Neurobiology of Aging</i> , 2004, 25, S419-S420.	1.5	2
366	Tau gene (MAPT) sequence variation among primates. <i>Gene</i> , 2004, 341, 313-322.	1.0	56
367	Genotype-phenotype correlations in FTDP-17: does form follow function?. <i>Experimental Neurology</i> , 2004, 187, 229-234.	2.0	12

#	ARTICLE	IF	CITATIONS
368	Following the leader: fibrillization of τ -synuclein and tau. <i>Experimental Neurology</i> , 2004, 187, 235-239.	2.0	13
369	Alzheimer's disease—a sum greater than its parts?. <i>Neurobiology of Aging</i> , 2004, 25, 725-733.	1.5	27
370	Deciphering the Molecular Basis of Memory Failure in Alzheimer's Disease. <i>Neuron</i> , 2004, 44, 181-193.	3.8	1,127
371	Tau protein and neurodegeneration. <i>Seminars in Cell and Developmental Biology</i> , 2004, 15, 45-49.	2.3	140
372	Induction of Inflammatory Mediators and Microglial Activation in Mice Transgenic for Mutant Human P301S Tau Protein. <i>American Journal of Pathology</i> , 2004, 165, 1643-1652.	1.9	180
373	Accelerated extinction of conditioned taste aversion in P301L tau transgenic mice. <i>Neurobiology of Disease</i> , 2004, 15, 500-509.	2.1	81
374	No evidence for tau duplications in frontal temporal dementia families showing genetic linkage to the tau locus in which tau mutations have not been found. <i>Neuroscience Letters</i> , 2004, 363, 99-101.	1.0	7
375	Amyloid β -induced neurofibrillary tangle formation in Alzheimer's disease: insight from transgenic mouse and tissue culture models. <i>International Journal of Developmental Neuroscience</i> , 2004, 22, 453-465.	0.7	122
376	CHIP and Hsp70 regulate tau ubiquitination, degradation and aggregation. <i>Human Molecular Genetics</i> , 2004, 13, 703-714.	1.4	613
377	Tau phosphorylation in neuronal cell function and dysfunction. <i>Journal of Cell Science</i> , 2004, 117, 5721-5729.	1.2	506
378	PAR-1 Kinase Plays an Initiator Role in a Temporally Ordered Phosphorylation Process that Confers Tau Toxicity in <i>Drosophila</i> . <i>Cell</i> , 2004, 116, 671-682.	13.5	323
379	Frontotemporal dementia with Pick-type histology associated with Q336R mutation in the tau gene. <i>Brain</i> , 2004, 127, 1415-1426.	3.7	87
380	Association between Tau polymorphism and male early-onset Alzheimer's disease. <i>NeuroReport</i> , 2004, 15, 175-179.	0.6	18
382	Tau Alternative Splicing and Frontotemporal Dementia. <i>Alzheimer Disease and Associated Disorders</i> , 2005, 19, S29-S36.	0.6	35
383	Neuropathologic, Biochemical, and Molecular Characterization of the Frontotemporal Dementias. <i>Journal of Neuropathology and Experimental Neurology</i> , 2005, 64, 420-428.	0.9	92
384	A New family with frontotemporal dementia with intronic 10+3 splice site mutation in the tau gene: neuropathology and molecular effects. <i>Neuropathology and Applied Neurobiology</i> , 2005, 31, 362-373.	1.8	23
385	Invertebrate models of Alzheimer's disease. <i>Genes, Brain and Behavior</i> , 2005, 4, 147-156.	1.1	89
386	Altered depression-related behavior and neurochemical changes in serotonergic neurons in mutant R406W human tau transgenic mice. <i>Brain Research</i> , 2005, 1059, 7-12.	1.1	44

#	ARTICLE	IF	CITATIONS
387	Frontotemporal dementia. <i>Lancet Neurology</i> , The, 2005, 4, 771-780.	4.9	492
388	Tau is central in the genetic Alzheimer's frontotemporal dementia spectrum. <i>Trends in Genetics</i> , 2005, 21, 664-672.	2.9	55
389	Progressive neurodegeneration in <i>C. elegans</i> model of tauopathy. <i>Neurobiology of Disease</i> , 2005, 20, 372-383.	2.1	98
390	Cerebrospinal fluid profile in frontotemporal dementia and Alzheimer's disease. <i>Annals of Neurology</i> , 2005, 57, 721-729.	2.8	217
391	Structural insights into Alzheimer filament assembly pathways based on site-directed mutagenesis and S-glutathionylation of three-repeat neuronal Tau protein. <i>Microscopy Research and Technique</i> , 2005, 67, 156-163.	1.2	26
392	Tau gene mutations and their effects. <i>Movement Disorders</i> , 2005, 20, S45-S52.	2.2	115
393	Metabolic/signal transduction hypothesis of Alzheimer's disease and other tauopathies. <i>Acta Neuropathologica</i> , 2005, 109, 25-31.	3.9	89
394	Familial frontotemporal dementia associated with the novel MAPT mutation T427M. <i>Journal of Neurology</i> , 2005, 252, 1543-1545.	1.8	13
395	Novel G335V mutation in the tau gene associated with early onset familial frontotemporal dementia. <i>Neurogenetics</i> , 2005, 6, 91-95.	0.7	39
396	Post-translational modifications of tau protein in Alzheimer's disease. <i>Journal of Neural Transmission</i> , 2005, 112, 813-838.	1.4	382
397	Understanding and treating neurodegeneration: insights from the flies. <i>Age</i> , 2005, 27, 225-239.	3.0	0
398	Neuronal cell death in human neurodegenerative diseases and their animal/cell models. , 2005, , 96-155.		1
399	Towards a Molecular Classification of Neurodegenerative Disease. <i>Research and Perspectives in Alzheimer's Disease</i> , 2005, , 11-23.	0.1	0
400	Metallothionein-I-II and GFAP positivity in the brains from frontotemporal dementia patients. <i>Journal of Alzheimer's Disease</i> , 2005, 8, 109-116.	1.2	13
401	Frontotemporal dementia with parkinsonism linked to Chromosome 17. , 2005, , 494-511.		0
402	Reprogramming of tau alternative splicing by spliceosome-mediated RNA trans-splicing: Implications for tauopathies. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2005, 102, 15659-15664.	3.3	55
403	Phosphorylation of FTDP-17 Mutant tau by Cyclin-dependent Kinase 5 Complexed with p35, p25, or p39. <i>Journal of Biological Chemistry</i> , 2005, 280, 31522-31529.	1.6	37
404	Transgenic Mouse Model of Tau Pathology in Astrocytes Leading to Nervous System Degeneration. <i>Journal of Neuroscience</i> , 2005, 25, 3539-3550.	1.7	166

#	ARTICLE	IF	CITATIONS
405	Neurodegeneration in Heterozygous Niemann-Pick Type C1 (NPC1) Mouse. <i>Journal of Biological Chemistry</i> , 2005, 280, 27296-27302.	1.6	39
406	Microtubule-binding drugs offset tau sequestration by stabilizing microtubules and reversing fast axonal transport deficits in a tauopathy model. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2005, 102, 227-231.	3.3	374
407	Tyrosine 394 Is Phosphorylated in Alzheimer's Paired Helical Filament Tau and in Fetal Tau with c-Abl as the Candidate Tyrosine Kinase. <i>Journal of Neuroscience</i> , 2005, 25, 6584-6593.	1.7	168
408	A novel mutation (K317M) in the MAPT gene causes FTDP and motor neuron disease. <i>Neurology</i> , 2005, 64, 1578-1585.	1.5	97
409	Increased tau Phosphorylation on Mitogen-Activated Protein Kinase Consensus Sites and Cognitive Decline in Transgenic Models for Alzheimer's Disease and FTDP-17: Evidence for Distinct Molecular Processes Underlying tau Abnormalities. <i>Molecular and Cellular Biology</i> , 2005, 25, 278-293.	1.1	51
410	Mapping the onset and progression of atrophy in familial frontotemporal lobar degeneration. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , 2005, 76, 162-168.	0.9	33
411	Proteomic and Functional Analyses Reveal a Mitochondrial Dysfunction in P301L Tau Transgenic Mice. <i>Journal of Biological Chemistry</i> , 2005, 280, 23802-23814.	1.6	362
412	High-density SNP haplotyping suggests altered regulation of tau gene expression in progressive supranuclear palsy. <i>Human Molecular Genetics</i> , 2005, 14, 3281-3292.	1.4	156
413	Disruption of the MAP1B-related Protein FUTSCH Leads to Changes in the Neuronal Cytoskeleton, Axonal Transport Defects, and Progressive Neurodegeneration in <i>Drosophila</i> . <i>Molecular Biology of the Cell</i> , 2005, 16, 2433-2442.	0.9	81
414	<i>tau</i> Haplotype and the <i>Saitohin</i> Q7R Gene Polymorphism Do Not Influence CSF Tau in Alzheimer's Disease and Are Not Associated with Frontotemporal Dementia or Parkinson's Disease. <i>Neurodegenerative Diseases</i> , 2005, 2, 28-35.	0.8	21
415	Hereditary Pick's disease with the G272V tau mutation shows predominant three-repeat tau pathology. <i>Brain</i> , 2005, 128, 2645-2653.	3.7	76
416	Inhibition of Heparin-induced Tau Filament Formation by Phenothiazines, Polyphenols, and Porphyrins. <i>Journal of Biological Chemistry</i> , 2005, 280, 7614-7623.	1.6	479
417	Quantitative analysis of tau isoform transcripts in sporadic tauopathies. <i>Molecular Brain Research</i> , 2005, 137, 104-109.	2.5	60
418	Alzheimer's disease: β , tau and synaptic dysfunction. <i>Trends in Molecular Medicine</i> , 2005, 11, 170-176.	3.5	388
419	Tau phosphorylation: physiological and pathological consequences. <i>Biochimica Et Biophysica Acta - Molecular Basis of Disease</i> , 2005, 1739, 280-297.	1.8	379
420	Tau alteration and neuronal degeneration in tauopathies: mechanisms and models. <i>Biochimica Et Biophysica Acta - Molecular Basis of Disease</i> , 2005, 1739, 331-354.	1.8	179
421	Can tau filaments be both physiologically beneficial and toxic?. <i>Biochimica Et Biophysica Acta - Molecular Basis of Disease</i> , 2005, 1739, 260-267.	1.8	12
422	Tau protein as a differential biomarker of tauopathies. <i>Biochimica Et Biophysica Acta - Molecular Basis of Disease</i> , 2005, 1739, 179-197.	1.8	262

#	ARTICLE	IF	CITATIONS
423	Mutations causing neurodegenerative tauopathies. <i>Biochimica Et Biophysica Acta - Molecular Basis of Disease</i> , 2005, 1739, 240-250.	1.8	347
424	Regulation of tau isoform expression and dementia. <i>Biochimica Et Biophysica Acta - Molecular Basis of Disease</i> , 2005, 1739, 104-115.	1.8	126
426	Tau pathology in Alzheimer disease and other tauopathies. <i>Biochimica Et Biophysica Acta - Molecular Basis of Disease</i> , 2005, 1739, 198-210.	1.8	786
427	Phosphorylated tau and the neurodegenerative foldopathies. <i>Biochimica Et Biophysica Acta - Molecular Basis of Disease</i> , 2005, 1739, 298-310.	1.8	115
428	Regulation of tau exon 10 splicing by a double stem-loop structure in mouse intron 10. <i>FEBS Letters</i> , 2005, 579, 241-244.	1.3	2
429	Effects of different anti-tau antibodies on tau fibrillogenesis: RTA-1 and RTA-2 counteract tau aggregation. <i>FEBS Letters</i> , 2005, 579, 1399-1404.	1.3	26
430	Nitration and oligomerization of tau induced by peroxynitrite inhibit its microtubule-binding activity. <i>FEBS Letters</i> , 2005, 579, 2421-2427.	1.3	40
431	Transgenic mice expressing mutant (N279K) human tau show mutation dependent cognitive deficits without neurofibrillary tangle formation. <i>FEBS Letters</i> , 2005, 579, 5704-5712.	1.3	51
432	The Alzheimer's Brain. <i>American Journal of Pathology</i> , 2005, 167, 1183-1188.	1.9	20
433	Accumulation of Filamentous Tau in the Cerebral Cortex of Human Tau R406W Transgenic Mice. <i>American Journal of Pathology</i> , 2005, 166, 521-531.	1.9	107
434	Early-onset Parkinson's disease in a Chinese population: 99mTc-TRODAT-1 SPECT, Parkin gene analysis and clinical study. <i>Parkinsonism and Related Disorders</i> , 2005, 11, 173-180.	1.1	37
435	Functional Genomics meets neurodegenerative disorders. <i>Progress in Neurobiology</i> , 2005, 76, 169-188.	2.8	42
436	Role of the protein tau in Alzheimer's disease. <i>Drug Discovery Today Disease Mechanisms</i> , 2005, 2, 395-400.	0.8	1
437	Ubiquitinated TDP-43 in Frontotemporal Lobar Degeneration and Amyotrophic Lateral Sclerosis. <i>Science</i> , 2006, 314, 130-133.	6.0	5,422
438	Cell-Cycle Markers in a Transgenic Mouse Model of Human Tauopathy. <i>American Journal of Pathology</i> , 2006, 168, 878-887.	1.9	35
439	Tau phosphorylation and aggregation in Alzheimer's disease pathology. <i>FEBS Letters</i> , 2006, 580, 2922-2927.	1.3	238
440	Regulation of phosphorylation of tau by cyclin-dependent kinase 5 and glycogen synthase kinase-3 at substrate level. <i>FEBS Letters</i> , 2006, 580, 5925-5933.	1.3	56
441	Folding of the Repeat Domain of Tau Upon Binding to Lipid Surfaces. <i>Journal of Molecular Biology</i> , 2006, 362, 312-326.	2.0	61

#	ARTICLE	IF	CITATIONS
442	Correlation of tau gene polymorphism with age at onset of Parkinson's disease. <i>Neuroscience Letters</i> , 2006, 405, 202-206.	1.0	8
443	The effects of APOE and tau gene variability on risk of frontotemporal dementia. <i>Neurobiology of Aging</i> , 2006, 27, 702-709.	1.5	56
444	A Hundred Years of Alzheimer's Disease Research. <i>Neuron</i> , 2006, 52, 3-13.	3.8	427
445	Early Alzheimer's disease genetics. <i>Journal of Alzheimer's Disease</i> , 2006, 9, 367-372.	1.2	4
446	Progress from Alzheimer's tangles to pathological tau points towards more effective therapies now. <i>Journal of Alzheimer's Disease</i> , 2006, 9, 257-262.	1.2	54
447	Discoveries of Tau, abnormally hyperphosphorylated tau and others of neurofibrillary degeneration: A personal historical perspective. <i>Journal of Alzheimer's Disease</i> , 2006, 9, 219-242.	1.2	95
448	Mutations in the tau gene (MAPT) in FTDP-17: The family with Multiple System Tauopathy with Presenile Dementia (MSTD). <i>Journal of Alzheimer's Disease</i> , 2006, 9, 373-380.	1.2	18
449	Novel splicing mutation in the progranulin gene causing familial corticobasal syndrome. <i>Brain</i> , 2006, 129, 3115-3123.	3.7	174
450	Genetically Engineered Mouse Models of Neurodegenerative Disorders. , 2006, , 371-408.		0
451	Of mice and men: more neurobiology in dementia. <i>Current Opinion in Psychiatry</i> , 2006, 19, 555-563.	3.1	24
452	Tangle Diseases and the Tau Haplotypes. <i>Alzheimer Disease and Associated Disorders</i> , 2006, 20, 60-62.	0.6	6
453	Tau protein, the paired helical filament and Alzheimer's disease. <i>Journal of Alzheimer's Disease</i> , 2006, 9, 195-207.	1.2	181
454	Tumor suppressor PTEN affects tau phosphorylation: deficiency in the phosphatase activity of PTEN increases aggregation of an FTDP-17 mutant Tau. <i>Molecular Neurodegeneration</i> , 2006, 1, 7.	4.4	14
455	Tauopathy: An overview. <i>Neuropathology</i> , 2006, 26, 455-456.	0.7	2
456	Neuropathology of familial tauopathy. <i>Neuropathology</i> , 2006, 26, 471-474.	0.7	16
457	Cellular tau pathology and immunohistochemical study of tau isoforms in sporadic tauopathies. <i>Neuropathology</i> , 2006, 26, 457-470.	0.7	93
458	Shift in the ratio of three-repeat tau and four-repeat tau mRNAs in individual cholinergic basal forebrain neurons in mild cognitive impairment and Alzheimer's disease. <i>Journal of Neurochemistry</i> , 2006, 96, 1401-1408.	2.1	93
459	Do axonal defects in tau and amyloid precursor protein transgenic animals model axonopathy in Alzheimer's disease?. <i>Journal of Neurochemistry</i> , 2006, 98, 993-1006.	2.1	113

#	ARTICLE	IF	CITATIONS
460	Sequential phosphorylation of tau protein by cAMP-dependent protein kinase and SAPK4/p38 β or JNK2 in the presence of heparin generates the AT100 epitope. <i>Journal of Neurochemistry</i> , 2006, 99, 154-164.	2.1	68
461	Genetic Factors in the Genesis of Alzheimer's Disease. <i>Annals of the New York Academy of Sciences</i> , 2000, 924, 1-7.	1.8	78
462	Pathways to Primary Neurodegenerative Disease. <i>Annals of the New York Academy of Sciences</i> , 2000, 924, 29-34.	1.8	18
463	Transgenic Mouse Models of Alzheimer's Disease. <i>Annals of the New York Academy of Sciences</i> , 2000, 908, 260-266.	1.8	79
464	Progress in Hereditary Tauopathies: A Mutation in the <i>Tau</i> Gene (G389R) Causes a Pick Disease-like Syndrome. <i>Annals of the New York Academy of Sciences</i> , 2000, 920, 52-62.	1.8	30
465	Molecular Genetics of Chromosome 17 Tauopathies. <i>Annals of the New York Academy of Sciences</i> , 2000, 920, 63-73.	1.8	83
466	<i>Tau</i> Gene Mutations in Frontotemporal Dementia and Parkinsonism Linked to Chromosome 17 (FTDP-17): Their Relevance for Understanding the Neurodegenerative Process. <i>Annals of the New York Academy of Sciences</i> , 2000, 920, 74-83.	1.8	54
467	Coexistent Tau and Amyloid Pathology in Hereditary Frontotemporal Dementia with Tau Mutations. <i>Annals of the New York Academy of Sciences</i> , 2000, 920, 115-119.	1.8	21
468	Impaired spatial reference memory and increased exploratory behavior in P301L tau transgenic mice. <i>Genes, Brain and Behavior</i> , 2006, 5, 369-379.	1.1	94
469	Comparison of extent of tau pathology in patients with frontotemporal dementia with Parkinsonism linked to chromosome 17 (FTDP-17), frontotemporal lobar degeneration with Pick bodies and early onset Alzheimer's disease. <i>Neuropathology and Applied Neurobiology</i> , 2006, 32, 374-387.	1.8	34
470	Single cell gene expression profiling in Alzheimer's disease. <i>NeuroRx</i> , 2006, 3, 302-318.	6.0	71
471	A Century of Alzheimer's Disease. <i>Science</i> , 2006, 314, 777-781.	6.0	1,798
472	An immunohistochemical study of cases of sporadic and inherited frontotemporal lobar degeneration using 3R- and 4R-specific tau monoclonal antibodies. <i>Acta Neuropathologica</i> , 2006, 111, 329-340.	3.9	91
473	Anti-amyloidogenic therapies: strategies for prevention and treatment of Alzheimer's disease. <i>Cellular and Molecular Life Sciences</i> , 2006, 63, 1538-1552.	2.4	79
474	Frontotemporal dementia. <i>Current Neurology and Neuroscience Reports</i> , 2006, 6, 481-489.	2.0	18
475	A decade of modeling Alzheimer's disease in transgenic mice. <i>Trends in Genetics</i> , 2006, 22, 281-289.	2.9	266
476	A MAPT mutation in a regulatory element upstream of exon 10 causes frontotemporal dementia. <i>Neurobiology of Disease</i> , 2006, 22, 401-403.	2.1	40
477	Modulation of neurosteroid production in human neuroblastoma cells by Alzheimer's disease key proteins. <i>Journal of Neurobiology</i> , 2006, 66, 868-881.	3.7	40

#	ARTICLE	IF	CITATIONS
478	Characteristics of frontotemporal dementia patients with aProgranulinmutation. <i>Annals of Neurology</i> , 2006, 60, 374-380.	2.8	83
479	A family with tau-negative frontotemporal dementia and neuronal intranuclear inclusions linked to chromosome 17. <i>Brain</i> , 2006, 129, 853-867.	3.7	102
480	A Belgian ancestral haplotype harbours a highly prevalent mutation for 17q21-linked tau-negative FTLD. <i>Brain</i> , 2006, 129, 841-852.	3.7	88
481	The neuropathology of frontotemporal lobar degeneration caused by mutations in the progranulin gene. <i>Brain</i> , 2006, 129, 3081-3090.	3.7	291
482	Dysregulation of Protein Phosphorylation/Dephosphorylation in Alzheimer's Disease: A Therapeutic Target. <i>Journal of Biomedicine and Biotechnology</i> , 2006, 2006, 1-11.	3.0	56
483	Molecular pathways that influence human tau-induced pathology in <i>Caenorhabditis elegans</i> . <i>Human Molecular Genetics</i> , 2006, 15, 1483-1496.	1.4	133
484	c-Jun N-terminal kinase hyperphosphorylates R406W tau at the PHF α 1 site during mitosis. <i>FASEB Journal</i> , 2006, 20, 762-764.	0.2	33
485	Polymerization of hyperphosphorylated tau into filaments eliminates its inhibitory activity. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2006, 103, 8864-8869.	3.3	174
486	Mutations in progranulin are a major cause of ubiquitin-positive frontotemporal lobar degeneration. <i>Human Molecular Genetics</i> , 2006, 15, 2988-3001.	1.4	529
487	Tumor suppressor PTEN affects tau phosphorylation, aggregation, and binding to microtubules. <i>FASEB Journal</i> , 2006, 20, 1272-1274.	0.2	58
488	Arginine/Serine-rich Protein Interaction Domain-dependent Modulation of a Tau Exon 10 Splicing Enhancer. <i>Journal of Biological Chemistry</i> , 2006, 281, 2460-2469.	1.6	44
489	Impaired Glutamate Transport in a Mouse Model of Tau Pathology in Astrocytes. <i>Journal of Neuroscience</i> , 2006, 26, 644-654.	1.7	109
490	Activation of PAR-1 Kinase and Stimulation of Tau Phosphorylation by Diverse Signals Require the Tumor Suppressor Protein LKB1. <i>Journal of Neuroscience</i> , 2007, 27, 574-581.	1.7	77
491	Corticotropin-Releasing Factor Receptors Differentially Regulate Stress-Induced Tau Phosphorylation. <i>Journal of Neuroscience</i> , 2007, 27, 6552-6562.	1.7	135
492	Immunotherapy Targeting Pathological Tau Conformers in a Tangle Mouse Model Reduces Brain Pathology with Associated Functional Improvements. <i>Journal of Neuroscience</i> , 2007, 27, 9115-9129.	1.7	468
493	Tau Aggregation and Toxicity in a Cell Culture Model of Tauopathy. <i>Journal of Biological Chemistry</i> , 2007, 282, 16454-16464.	1.6	117
494	Accumulation of Pathological Tau Species and Memory Loss in a Conditional Model of Tauopathy. <i>Journal of Neuroscience</i> , 2007, 27, 3650-3662.	1.7	438
495	Frontotemporal Dementia with Tau Pathology. <i>Neurodegenerative Diseases</i> , 2007, 4, 236-253.	0.8	69

#	ARTICLE	IF	CITATIONS
496	The Tau N279K Exon 10 Splicing Mutation Recapitulates Frontotemporal Dementia and Parkinsonism Linked to Chromosome 17 Tauopathy in a Mouse Model. <i>Journal of Neuroscience</i> , 2007, 27, 9155-9168.	1.7	68
497	A novel progranulin mutation associated with variable clinical presentation and tau, TDP43 and alpha-synuclein pathology. <i>Brain</i> , 2007, 130, 1360-1374.	3.7	124
498	Chapter 4 Tau Protein and the Dementias. <i>Blue Books of Neurology</i> , 2007, , 88-111.	0.1	0
499	Fibrillogenic Nuclei Composed of P301L Mutant Tau Induce Elongation of P301L Tau but Not Wild-type Tau*. <i>Journal of Biological Chemistry</i> , 2007, 282, 20309-20318.	1.6	71
500	Cognition and Amyotrophic Lateral Sclerosis (ALS). <i>American Journal of Alzheimer's Disease and Other Dementias</i> , 2007, 22, 300-312.	0.9	44
501	Cytoskeleton proteins are modulators of mutant tau-induced neurodegeneration in <i>Drosophila</i> . <i>Human Molecular Genetics</i> , 2007, 16, 555-566.	1.4	107
502	Impairments in impulse control in mice transgenic for the human FTDP-17 tau V337M mutation are exacerbated by age. <i>Human Molecular Genetics</i> , 2007, 16, 1708-1719.	1.4	32
503	Expression, localization and tau exon 10 splicing activity of the brain RNA-binding protein TNRC4. <i>Human Molecular Genetics</i> , 2007, 16, 2760-2769.	1.4	16
504	Parkinsonism-Plus Syndromes and Secondary Parkinsonian Disorders. , 2007, , 233-284.		3
505	Progressive Nonfluent Aphasia Associated With a New Mutation V363I in Tau Gene. <i>American Journal of Alzheimer's Disease and Other Dementias</i> , 2007, 22, 294-299.	0.9	46
506	TDP-43 Proteinopathy in Frontotemporal Lobar Degeneration and Amyotrophic Lateral Sclerosis. <i>Archives of Neurology</i> , 2007, 64, 1388.	4.9	179
507	SUT-1 enables tau-induced neurotoxicity in <i>C. elegans</i> . <i>Human Molecular Genetics</i> , 2007, 16, 1959-1971.	1.4	62
508	Clinicopathologic features of frontotemporal dementia with Progranulin sequence variation. <i>Neurology</i> , 2007, 68, 820-827.	1.5	73
509	The genetics of frontotemporal lobar degeneration. <i>Current Opinion in Neurology</i> , 2007, 20, 693-698.	1.8	8
510	Frontotemporal Dementia and Semantic Dementia. <i>Alzheimer Disease and Associated Disorders</i> , 2007, 21, S19-S22.	0.6	11
511	Diagnostic Criteria for the Behavioral Variant of Frontotemporal Dementia (bvFTD): Current Limitations and Future Directions. <i>Alzheimer Disease and Associated Disorders</i> , 2007, 21, S14-S18.	0.6	219
512	TDP-43-Positive White Matter Pathology in Frontotemporal Lobar Degeneration With Ubiquitin-Positive Inclusions. <i>Journal of Neuropathology and Experimental Neurology</i> , 2007, 66, 177-183.	0.9	201
513	The $\hat{\tau}$ K280 Mutation in MAP tau Favors Exon 10 Skipping In Vivo. <i>Journal of Neuropathology and Experimental Neurology</i> , 2007, 66, 17-25.	0.9	50

#	ARTICLE	IF	CITATIONS
514	A Familial Form of Pallidoluyisionigral Degeneration and Amyotrophic Lateral Sclerosis With Divergent Clinical Presentations. <i>Journal of Neuropathology and Experimental Neurology</i> , 2007, 66, 650-659.	0.9	4
515	A Reassessment of the Neuropathology of Frontotemporal Dementia Linked to Chromosome 3. <i>Journal of Neuropathology and Experimental Neurology</i> , 2007, 66, 884-891.	0.9	118
516	The complex aetiology of frontotemporal lobar degeneration. <i>Experimental Neurology</i> , 2007, 206, 1-10.	2.0	28
518	Phosphorylation of human microtubule-associated protein tau by protein kinases of the AGC subfamily. <i>FEBS Letters</i> , 2007, 581, 2657-2662.	1.3	24
519	Genetics and dementia: Risk factors, diagnosis, and management. <i>Alzheimer's and Dementia</i> , 2007, 3, 418-427.	0.4	35
520	The Genetics of Alzheimer's Disease. <i>American Journal of Alzheimer's Disease and Other Dementias</i> , 2007, 22, 37-41.	0.9	31
521	Two sites in the MAPT region confer genetic risk for Guam ALS/PDC and dementia. <i>Human Molecular Genetics</i> , 2007, 16, 295-306.	1.4	59
522	The Genetics of Frontotemporal Dementia. <i>Neurologic Clinics</i> , 2007, 25, 697-715.	0.8	13
523	The Clinical Overlap between the Corticobasal Degeneration Syndrome and Other Diseases of the Frontotemporal Spectrum: Three Case Reports. <i>Behavioural Neurology</i> , 2007, 18, 159-164.	1.1	10
524	Molecular genetics of Alzheimer's disease and other adult-onset dementias. , 0, , 439-453.		0
525	Epidemiology of frontotemporal dementia. , 0, , 25-37.		2
526	Prediction of psychosis onset in Alzheimer disease: The role of depression symptom severity and the HTR2A T102C polymorphism. <i>American Journal of Medical Genetics Part B: Neuropsychiatric Genetics</i> , 2007, 144B, 1054-1062.	1.1	26
527	Association analysis of MAPT H1 haplotype and subhaplotypes in Parkinson's disease. <i>Annals of Neurology</i> , 2007, 62, 137-144.	2.8	129
528	Progranulin null mutations in both sporadic and familial frontotemporal dementia. <i>Human Mutation</i> , 2007, 28, 846-855.	1.1	162
529	S/P and T/P phosphorylation is critical for tau neurotoxicity in <i>Drosophila</i> . <i>Journal of Neuroscience Research</i> , 2007, 85, 1271-1278.	1.3	108
530	A Decade of Tau Transgenic Animal Models and Beyond. <i>Brain Pathology</i> , 2007, 17, 91-103.	2.1	145
531	Hereditary Frontotemporal Dementia Caused by Tau Gene Mutations. <i>Brain Pathology</i> , 2007, 17, 63-73.	2.1	182
532	Structural Principles of Tau and the Paired Helical Filaments of Alzheimer's Disease. <i>Brain Pathology</i> , 2007, 17, 83-90.	2.1	221

#	ARTICLE	IF	CITATIONS
533	Progressive Supranuclear Palsy: Pathology and Genetics. <i>Brain Pathology</i> , 2007, 17, 74-82.	2.1	249
534	Frontotemporal Lobar Degeneration: Current Concepts in the Light of Recent Advances. <i>Brain Pathology</i> , 2007, 17, 104-114.	2.1	66
535	Progranulin: normal function and role in neurodegeneration. <i>Journal of Neurochemistry</i> , 2008, 104, 287-297.	2.1	114
536	The tau S305S mutation causes frontotemporal dementia with parkinsonism. <i>European Journal of Neurology</i> , 2008, 15, 156-161.	1.7	27
537	Concurrence of TDP-43, tau and α -synuclein pathology in brains of Alzheimer's disease and dementia with Lewy bodies. <i>Brain Research</i> , 2007, 1184, 284-294.	1.1	349
538	Alzheimer neurofibrillary degeneration: significance, etiopathogenesis, therapeutics and prevention. <i>Journal of Cellular and Molecular Medicine</i> , 2008, 12, 38-55.	1.6	200
539	Phenotypic variability associated with progranulin haploinsufficiency in patients with the common 1477C>T (Arg493X) mutation: an international initiative. <i>Lancet Neurology</i> , The, 2007, 6, 857-868.	4.9	199
540	Transgenic animal models of neurodegenerative diseases and their application to treatment development. <i>Advanced Drug Delivery Reviews</i> , 2007, 59, 1093-1102.	6.6	77
541	Developing pharmacological therapies for Alzheimer disease. <i>Cellular and Molecular Life Sciences</i> , 2007, 64, 2234-2244.	2.4	41
542	Study of tauopathies by comparing <i>Drosophila</i> and human tau in <i>Drosophila</i> . <i>Cell and Tissue Research</i> , 2007, 329, 169-178.	1.5	32
543	The novel Tau mutation G335S: clinical, neuropathological and molecular characterization. <i>Acta Neuropathologica</i> , 2007, 113, 461-470.	3.9	34
544	<i>Lrrk2</i> and chronic inflammation are linked to pallido-ponto-nigral degeneration caused by the N279K tau mutation. <i>Acta Neuropathologica</i> , 2007, 114, 243-254.	3.9	20
545	Progranulin and frontotemporal lobar degeneration. <i>Acta Neuropathologica</i> , 2007, 114, 39-47.	3.9	23
546	Tauopathy models and human neuropathology: similarities and differences. <i>Acta Neuropathologica</i> , 2007, 115, 39-53.	3.9	44
547	The molecular genetics and neuropathology of frontotemporal lobar degeneration: recent developments. <i>Neurogenetics</i> , 2007, 8, 237-248.	0.7	76
549	Tau exon 10 alternative splicing and tauopathies. <i>Molecular Neurodegeneration</i> , 2008, 3, 8.	4.4	225
550	The G389R mutation in the <i>MAPT</i> gene presenting as sporadic corticobasal syndrome. <i>Movement Disorders</i> , 2008, 23, 892-895.	2.2	43
551	Tau isoform regulation is region- and cell-specific in mouse brain. <i>Journal of Comparative Neurology</i> , 2008, 511, 788-803.	0.9	139

#	ARTICLE	IF	CITATIONS
552	Progranulin locus deletion in frontotemporal dementia. <i>Human Mutation</i> , 2008, 29, 53-58.	1.1	85
553	Granulin mutations associated with frontotemporal lobar degeneration and related disorders: An update. <i>Human Mutation</i> , 2008, 29, 1373-1386.	1.1	126
554	Tau-Based Treatment Strategies in Neurodegenerative Diseases. <i>Neurotherapeutics</i> , 2008, 5, 443-457.	2.1	128
555	Neurogenesis and cell cycle-reactivated neuronal death during pathogenic tau aggregation. <i>Genes, Brain and Behavior</i> , 2008, 7, 92-100.	1.1	48
556	Animal models of Alzheimer's disease and frontotemporal dementia. <i>Nature Reviews Neuroscience</i> , 2008, 9, 532-544.	4.9	604
557	Alternative splicing of exon 10 in the tau gene as a target for treatment of tauopathies. <i>BMC Neuroscience</i> , 2008, 9, S10.	0.8	33
558	Detection of filamentous tau inclusions by the fluorescent Congo red derivative FSB [(1-fluoro-2,5-bis(3-hydroxycarbonyl-4-hydroxy)styryl)benzene]. <i>FEBS Letters</i> , 2008, 582, 901-906.	4.3	38
559	Mutations in progranulin (GRN) within the spectrum of clinical and pathological phenotypes of frontotemporal dementia. <i>Lancet Neurology</i> , The, 2008, 7, 965-974.	4.9	203
560	Motor alterations are reduced in mice lacking the PARK2 gene in the presence of a human FTDP-17 mutant form of four-repeat tau. <i>Journal of the Neurological Sciences</i> , 2008, 275, 139-144.	0.3	7
561	Genetics of Parkinson's Disease. , 2008, , 9-33.		2
562	Protein Folding and Aggregation in in vitro Models of Parkinson's Disease. , 2008, , 575-595.		11
563	A novel deletion in progranulin gene is associated with FTDP-17 and CBS. <i>Neurobiology of Aging</i> , 2008, 29, 427-435.	1.5	109
564	Memory and exploratory impairment in mice that lack the Park-2 gene and that over-express the human FTDP-17 mutant Tau. <i>Behavioural Brain Research</i> , 2008, 189, 350-356.	1.2	12
565	Biochemistry and Molecular Biology of Amyloid Î²-Protein and the Mechanism of Alzheimer's Disease. <i>Handbook of Clinical Neurology</i> / Edited By P J Vinken and G W Bruyn, 2008, 89, 245-260.	1.0	116
566	Analysis of Tau Phosphorylation and Truncation in a Mouse Model of Human Tauopathy. <i>American Journal of Pathology</i> , 2008, 172, 123-131.	1.9	113
567	TDP-43 is a culprit in human neurodegeneration, and not just an innocent bystander. <i>Mammalian Genome</i> , 2008, 19, 299-305.	1.0	63
568	TDP-43 in neurodegenerative disorders. <i>Expert Opinion on Biological Therapy</i> , 2008, 8, 969-978.	1.4	39
569	Frontotemporal lobar degeneration: clinical and pathologic overview. <i>Handbook of Clinical Neurology</i> / Edited By P J Vinken and G W Bruyn, 2008, 89, 343-364.	1.0	10

#	ARTICLE	IF	CITATIONS
570	Clinical aspects of hereditary frontotemporal dementia. Handbook of Clinical Neurology / Edited By P J Vinken and G W Bruyn, 2008, 89, 365-376.	1.0	0
571	Epidemiological aspects of frontotemporal dementia. Handbook of Clinical Neurology / Edited By P J Vinken and G W Bruyn, 2008, 89, 331-341.	1.0	5
572	The tauopathy associated with mutation +3 in intron 10 of Tau: characterization of the MSTD family. Brain, 2008, 131, 72-89.	3.7	98
573	A distinct clinical, neuropsychological and radiological phenotype is associated with progranulin gene mutations in a large UK series. Brain, 2008, 131, 706-720.	3.7	222
574	The genetics of frontotemporal dementia. Handbook of Clinical Neurology / Edited By P J Vinken and G W Bruyn, 2008, 89, 383-392.	1.0	3
575	Biological Models in Frontotemporal Dementias. Handbook of Clinical Neurology / Edited By P J Vinken and G W Bruyn, 2008, 89, 449-455.	1.0	0
576	Biologic models of neurodegenerative disorders. Handbook of Clinical Neurology / Edited By P J Vinken and G W Bruyn, 2008, 89, 173-188.	1.0	3
577	Biological Transgenic Mouse Models of Alzheimer's Disease. Handbook of Clinical Neurology / Edited By P J Vinken and G W Bruyn, 2008, 89, 291-301.	1.0	2
578	CORTICOBASAL SYNDROME AND PRIMARY PROGRESSIVE APHASIA AS MANIFESTATIONS OF <i>LRRK2</i> GENE MUTATIONS. Neurology, 2008, 71, 303-304.	1.5	15
579	Corticobasal syndrome and primary progressive aphasia as manifestations of <i>LRRK2</i> gene mutations. Neurology, 2008, 70, 521-527.	1.5	63
580	CSF biomarkers in frontotemporal lobar degeneration with known pathology. Neurology, 2008, 70, 1827-1835.	1.5	207
581	Neuropathology of Hereditary Forms of Frontotemporal Dementia and Parkinsonism. Handbook of Clinical Neurology / Edited By P J Vinken and G W Bruyn, 2008, 89, 393-414.	1.0	10
582	New Genes, New Dilemmas: FTLG Genetics and Its Implications for Families. American Journal of Alzheimer's Disease and Other Dementias, 2008, 22, 507-515.	0.9	23
583	Phenotype variability in progranulin mutation carriers: a clinical, neuropsychological, imaging and genetic study. Brain, 2008, 131, 732-746.	3.7	331
584	APOE, APOE Promoter, and Tau Genotypes and Risk for Concussion in College Athletes. Clinical Journal of Sport Medicine, 2008, 18, 10-17.	0.9	107
585	Update on Recent Molecular and Genetic Advances in Frontotemporal Lobar Degeneration. Journal of Neuropathology and Experimental Neurology, 2008, 67, 635-648.	0.9	32
586	White Matter Tauopathy With Globular Glial Inclusions: A Distinct Sporadic Frontotemporal Lobar Degeneration. Journal of Neuropathology and Experimental Neurology, 2008, 67, 963-975.	0.9	111
587	New approaches to the treatment of frontotemporal lobar degeneration. Current Opinion in Neurology, 2008, 21, 708-716.	1.8	58

#	ARTICLE	IF	CITATIONS
588	Neurodegenerative disorders. , 2008, , 39-89.		1
589	Park2-Null/Tau Transgenic Mice Reveal a Functional Relationship between Parkin and Tau. Journal of Alzheimer's Disease, 2008, 13, 161-172.	1.2	17
590	Inflammation in Neurodegenerative Disorders: Friend or Foe?. Current Aging Science, 2008, 1, 30-41.	0.4	35
591	Cytosolic Abnormally Hyperphosphorylated Tau But Not Paired Helical Filaments Sequester Normal MAPs and Inhibit Microtubule Assembly. Journal of Alzheimer's Disease, 2008, 14, 365-370.	1.2	76
592	Immunotherapy Targeting Pathological Tau Protein in Alzheimer's Disease and Related Tauopathies. Journal of Alzheimer's Disease, 2008, 15, 157-168.	1.2	107
593	An update on the toxicity of Aβ in Alzheimer's disease. Neuropsychiatric Disease and Treatment, 2008, 4, 1033.	1.0	32
594	Differential Incorporation of Tau Isoforms in Alzheimer's Disease. Journal of Alzheimer's Disease, 2008, 14, 1-16.	1.2	107
595	Exonic Point Mutations of Human Tau Enhance its Toxicity and Cause Characteristic Changes in Neuronal Morphology, Tau Distribution and Tau Phosphorylation in the Lamprey Cellular Model of Tauopathy. Journal of Alzheimer's Disease, 2009, 16, 99-111.	1.2	19
596	The molecular basis of frontotemporal dementia. Expert Reviews in Molecular Medicine, 2009, 11, e23.	1.6	69
597	Tau Mutations in Neurodegenerative Diseases. Journal of Biological Chemistry, 2009, 284, 6021-6025.	1.6	140
598	Propagation of Tau Misfolding from the Outside to the Inside of a Cell. Journal of Biological Chemistry, 2009, 284, 12845-12852.	1.6	1,043
599	Effect of Pin1 or Microtubule Binding on Dephosphorylation of FTDP-17 Mutant Tau. Journal of Biological Chemistry, 2009, 284, 16840-16847.	1.6	22
600	Conformational Diversity of Wild-type Tau Fibrils Specified by Templated Conformation Change. Journal of Biological Chemistry, 2009, 284, 3546-3551.	1.6	200
601	The Model Caenorhabditis elegans in Diabetes Mellitus and Alzheimer's Disease. Journal of Alzheimer's Disease, 2009, 16, 897-908.	1.2	28
602	SUT-2 potentiates tau-induced neurotoxicity in Caenorhabditis elegans. Human Molecular Genetics, 2009, 18, 1825-1838.	1.4	86
603	Correction of tau mis-splicing caused by FTDP-17 MAPT mutations by spliceosome-mediated RNA trans-splicing. Human Molecular Genetics, 2009, 18, 3266-3273.	1.4	50
604	No Evidence of PGRN or MAPT Gene Dosage Alterations in a Collection of Patients with Frontotemporal Lobar Degeneration. Dementia and Geriatric Cognitive Disorders, 2009, 28, 456-460.	0.7	6
605	Accumulation of tau induced in neurites by microglial proinflammatory mediators. FASEB Journal, 2009, 23, 2502-2513.	0.2	127

#	ARTICLE	IF	CITATIONS
606	Frontotemporal dementia in a large Swedish family is caused by a progranulin null mutation. <i>Neurogenetics</i> , 2009, 10, 27-34.	0.7	16
607	Recent origin and spread of a common Welsh MAPT splice mutation causing frontotemporal lobar degeneration. <i>Neurogenetics</i> , 2009, 10, 313-318.	0.7	10
608	Recent advances in using <i>Drosophila</i> to model neurodegenerative diseases. <i>Apoptosis: an International Journal on Programmed Cell Death</i> , 2009, 14, 1008-1020.	2.2	28
609	Hyperphosphorylated tau aggregates in the cortex and hippocampus of transgenic mice with mutant human FTDP-17 Tau and lacking the PARK2 gene. <i>Acta Neuropathologica</i> , 2009, 117, 159-168.	3.9	13
610	Mechanisms of tau-induced neurodegeneration. <i>Acta Neuropathologica</i> , 2009, 118, 53-69.	3.9	577
611	Versatile Somatic Gene Transfer for Modeling Neurodegenerative Diseases. <i>Neurotoxicity Research</i> , 2009, 16, 329-342.	1.3	11
612	What have worm models told us about the mechanisms of neuronal dysfunction in human neurodegenerative diseases?. <i>Molecular Neurodegeneration</i> , 2009, 4, 38.	4.4	62
613	Transmission and spreading of tauopathy in transgenic mouse brain. <i>Nature Cell Biology</i> , 2009, 11, 909-913.	4.6	1,515
614	What is "early onset dementia"? <i>Psychogeriatrics</i> , 2009, 9, 67-72.	0.6	26
615	The amyloid hypothesis for Alzheimer's disease: a critical reappraisal. <i>Journal of Neurochemistry</i> , 2009, 110, 1129-1134.	2.1	700
616	Inhibition of tau fibrillization by oleocanthal via reaction with the amino groups of tau. <i>Journal of Neurochemistry</i> , 2009, 110, 1339-1351.	2.1	174
617	Structural Basis for Stabilization of the Tau Pre-mRNA Splicing Regulatory Element by Novantrone (Mitoxantrone). <i>Chemistry and Biology</i> , 2009, 16, 557-566.	6.2	82
618	Tau pathophysiology in neurodegeneration: a tangled issue. <i>Trends in Neurosciences</i> , 2009, 32, 150-159.	4.2	284
619	Knock-out and transgenic mouse models of tauopathies. <i>Neurobiology of Aging</i> , 2009, 30, 1-13.	1.5	96
620	Clinical and pathological features of an Alzheimer's disease patient with the MAPT ^{K280} mutation. <i>Neurobiology of Aging</i> , 2009, 30, 388-393.	1.5	55
621	Novel PSEN1 and PGRN mutations in early-onset familial frontotemporal dementia. <i>Neurobiology of Aging</i> , 2009, 30, 1825-1833.	1.5	48
622	FTDP-17 missense mutations site-specifically inhibit as well as promote dephosphorylation of microtubule-associated protein tau by protein phosphatases of HEK-293 cell extract. <i>Neurochemistry International</i> , 2009, 54, 14-27.	1.9	7
623	Intrafamilial clinical phenotypic heterogeneity with MAPT gene splice site IVS10+16C>T mutation. <i>Journal of the Neurological Sciences</i> , 2009, 287, 253-256.	0.3	18

#	ARTICLE	IF	CITATIONS
625	<i>Drosophila</i> Models of Neurodegenerative Diseases. Annual Review of Pathology: Mechanisms of Disease, 2009, 4, 315-342.	9.6	204
626	Frontotemporal dementia presenting as schizophrenia-like psychosis in young people: clinicopathological series and review of cases. British Journal of Psychiatry, 2009, 194, 298-305.	1.7	166
627	Overexpression of Wild-Type Murine Tau Results in Progressive Tauopathy and Neurodegeneration. American Journal of Pathology, 2009, 175, 1598-1609.	1.9	56
628	Frontotemporal dementia. , 0, , 45-55.		0
629	Animal models of dementia. , 0, , 131-141.		0
630	Increased Association Between Rough Endoplasmic Reticulum Membranes and Mitochondria in Transgenic Mice That Express P301L Tau. Journal of Neuro pathology and Experimental Neurology, 2009, 68, 503-514.	0.9	58
631	Amyloid precursor protein and tau transgenic models of Alzheimer's disease: insights from the past and directions for the future. Future Neurology, 2010, 5, 411-420.	0.9	4
632	Alzheimer's disease neurofibrillary degeneration: pivotal and multifactorial. Biochemical Society Transactions, 2010, 38, 962-966.	1.6	58
633	The Genetics of Parkinson Disease. Journal of Geriatric Psychiatry and Neurology, 2010, 23, 228-242.	1.2	259
634	Contemporary Approaches to Alzheimer's Disease and Frontotemporal Dementia. Methods in Molecular Biology, 2010, 670, 1-9.	0.4	7
635	Novel MAPT Val75Ala mutation and PSEN2 Arg62His in two siblings with frontotemporal dementia. Neurological Sciences, 2010, 31, 65-70.	0.9	15
636	Tau pathology: predictive diagnostics, targeted preventive and personalized medicine and application of advanced research in medical practice. EPMA Journal, 2010, 1, 305-316.	3.3	7
637	Frontotemporal Dementia and Primary Progressive Aphasia: An Update. Current Neurology and Neuroscience Reports, 2010, 10, 504-511.	2.0	17
638	Phosphorylation of Tau at S422 is enhanced by A β 2 in TauPS2APP triple transgenic mice. Neurobiology of Disease, 2010, 37, 294-306.	2.1	99
639	Non-apoptotic cell death in <i>Caenorhabditis elegans</i>. Developmental Dynamics, 2010, 239, 1337-1351.	0.8	21
640	Pathogenic cysteine mutations affect progranulin function and production of mature granulins. Journal of Neurochemistry, 2010, 112, 1305-1315.	2.1	76
641	Review: Recent progress in frontotemporal lobar degeneration. Neuro pathology and Applied Neurobiology, 2010, 36, 4-16.	1.8	9
642	A Tangled Web " Tau and Sporadic Parkinson's Disease. Frontiers in Psychiatry, 2010, 1, 150.	1.3	27

#	ARTICLE	IF	CITATIONS
643	Human Stem Cell-Derived Neurons: A System to Study Human Tau Function and Dysfunction. PLoS ONE, 2010, 5, e13947.	1.1	31
644	Three Repeat Isoforms of Tau Inhibit Assembly of Four Repeat Tau Filaments. PLoS ONE, 2010, 5, e10810.	1.1	82
646	Kinesin-1 transport reductions enhance human tau hyperphosphorylation, aggregation and neurodegeneration in animal models of tauopathies. Human Molecular Genetics, 2010, 19, 4399-4408.	1.4	58
647	Genetic Causes of Frontotemporal Degeneration. Journal of Geriatric Psychiatry and Neurology, 2010, 23, 260-268.	1.2	28
648	Cell-Mediated Neuroprotection in a Mouse Model of Human Tauopathy. Journal of Neuroscience, 2010, 30, 9973-9983.	1.7	106
649	Phosphorylation of Tau at Thr212, Thr231, and Ser262 Combined Causes Neurodegeneration. Journal of Biological Chemistry, 2010, 285, 30851-30860.	1.6	177
650	Three- and Four-repeat Tau Coassemble into Heterogeneous Filaments. Journal of Biological Chemistry, 2010, 285, 37920-37926.	1.6	56
651	Reimagining Alzheimer's Disease—An Age-Based Hypothesis. Journal of Neuroscience, 2010, 30, 16755-16762.	1.7	330
652	Lysosomal Dysfunction Promotes Cleavage and Neurotoxicity of Tau In Vivo. PLoS Genetics, 2010, 6, e1001026.	1.5	132
653	Proteases and Proteolysis in Alzheimer Disease: A Multifactorial View on the Disease Process. Physiological Reviews, 2010, 90, 465-494.	13.1	389
654	Tau in Alzheimer Disease and Related Tauopathies. Current Alzheimer Research, 2010, 7, 656-664.	0.7	822
655	Targeting Tau Protein in Alzheimer's Disease. Drugs and Aging, 2010, 27, 351-365.	1.3	82
656	Semantic dementia associated with mutation V363I in the tau gene. Journal of the Neurological Sciences, 2010, 296, 112-114.	0.3	39
657	SJLB mice develop tauopathy-induced parkinsonism. Neuroscience Letters, 2010, 473, 182-185.	1.0	7
658	Sodium selenate specifically activates PP2A phosphatase, dephosphorylates tau and reverses memory deficits in an Alzheimer's disease model. Journal of Clinical Neuroscience, 2010, 17, 1025-1033.	0.8	134
659	Animal models reveal role for tau phosphorylation in human disease. Biochimica Et Biophysica Acta - Molecular Basis of Disease, 2010, 1802, 860-871.	1.8	67
660	In-vivo visualization of key molecular processes involved in Alzheimer's disease pathogenesis: Insights from neuroimaging research in humans and rodent models. Biochimica Et Biophysica Acta - Molecular Basis of Disease, 2010, 1802, 373-388.	1.8	20
661	Mouse models in neurological disorders: Applications of non-invasive imaging. Biochimica Et Biophysica Acta - Molecular Basis of Disease, 2010, 1802, 819-839.	1.8	42

#	ARTICLE	IF	CITATIONS
662	Early behavioural markers of disease in P301S tau transgenic mice. Behavioural Brain Research, 2010, 208, 250-257.	1.2	76
663	The propagation of prion-like protein inclusions in neurodegenerative diseases. Trends in Neurosciences, 2010, 33, 317-325.	4.2	402
664	REVIEW: Curcumin and Alzheimer's Disease. CNS Neuroscience and Therapeutics, 2010, 16, 285-297.	1.9	367
665	New Approaches to the Pathology and Genetics of Neurodegeneration. American Journal of Pathology, 2010, 176, 2058-2066.	1.9	15
666	TAR DNA-binding protein 43 in neurodegenerative disease. Nature Reviews Neurology, 2010, 6, 211-220.	4.9	396
667	Sensitivity of revised diagnostic criteria for the behavioural variant of frontotemporal dementia. Brain, 2011, 134, 2456-2477.	3.7	3,913
669	Tau Pathology. Advances in Neurobiology, 2011, , 83-132.	1.3	1
670	Biomarkers, Genetics, and Risk Factors for Concussion. PM and R, 2011, 3, S452-9.	0.9	38
671	Troubles de lâ€™attention chez un homme de 71ans. Pratique Neurologique - FMC, 2011, 2, 215-228.	0.1	0
672	The acetylation of tau inhibits its function and promotes pathological tau aggregation. Nature Communications, 2011, 2, 252.	5.8	554
673	Combined expression of tau and the Harlequin mouse mutation leads to increased mitochondrial dysfunction, tau pathology and neurodegeneration. Neurobiology of Aging, 2011, 32, 1827-1838.	1.5	27
674	No association of psychosis in Alzheimer disease with neurodegenerative pathway genes. Neurobiology of Aging, 2011, 32, 555.e9-555.e11.	1.5	18
675	Compound heterozygosity of 2 novel MAPT mutations in frontotemporal dementia. Neurobiology of Aging, 2011, 32, 757.e1-757.e11.	1.5	13
676	Genetic players in multiple system atrophy: unfolding the nature of the beast. Neurobiology of Aging, 2011, 32, 1924.e5-1924.e14.	1.5	39
677	The Role of Tau in Alzheimer's Disease and Related Disorders. CNS Neuroscience and Therapeutics, 2011, 17, 514-524.	1.9	195
678	PET Applications in Animal Models of Neurodegenerative and Neuroinflammatory Disorders. Current Topics in Behavioral Neurosciences, 2011, 11, 45-64.	0.8	3
679	Yeast as a Model System to Study Tau Biology. International Journal of Alzheimer's Disease, 2011, 2011, 1-16.	1.1	25
680	Identifying the genetic components underlying the pathophysiology of movement disorders. The Application of Clinical Genetics, 2011, 4, 81.	1.4	1

#	ARTICLE	IF	CITATIONS
681	Amyloid Hypothesis and Alzheimer's Disease. , 2011, , .		3
682	Mechanistic Studies of Antibody-Mediated Clearance of Tau Aggregates Using an ex vivo Brain Slice Model. <i>Frontiers in Psychiatry</i> , 2011, 2, 59.	1.3	71
683	Genetic basis of Parkinson's disease: inheritance, penetrance, and expression. <i>The Application of Clinical Genetics</i> , 2011, 4, 67.	1.4	96
684	Implicating Calpain in Tau-Mediated Toxicity In Vivo. <i>PLoS ONE</i> , 2011, 6, e23865.	1.1	45
685	A Novel Pathogenic PSEN1 Mutation in a Family with Alzheimer's Disease: Phenotypical and Neuropathological Features. <i>Journal of Alzheimer's Disease</i> , 2011, 25, 425-431.	1.2	14
686	Genetic Contributors to Frontotemporal Lobar Degeneration: Beyond Monogenic Disease. <i>Mini-Reviews in Medicinal Chemistry</i> , 2011, 11, 988-1001.	1.1	3
687	Tau as a Therapeutic Target for Alzheimers Disease. <i>Current Alzheimer Research</i> , 2011, 8, 666-677.	0.7	65
689	Lipopolysaccharide-induced tau phosphorylation and kinase activity - modulation, but not mediation, by corticotropin-releasing factor receptors. <i>European Journal of Neuroscience</i> , 2011, 34, 448-456.	1.2	39
690	Frontotemporal dementia and parkinsonism linked to chromosome 17 - the first Polish family. <i>European Journal of Neurology</i> , 2011, 18, 535-537.	1.7	11
691	Therapeutic applications of antibodies in non-infectious neurodegenerative diseases. <i>New Biotechnology</i> , 2011, 28, 511-517.	2.4	7
692	Alzheimer's Disease: The Challenge of the Second Century. <i>Science Translational Medicine</i> , 2011, 3, 77sr1.	5.8	1,109
693	Globular glial tauopathies (GGT) presenting with motor neuron disease or frontotemporal dementia: an emerging group of 4-repeat tauopathies. <i>Acta Neuropathologica</i> , 2011, 122, 415-428.	3.9	67
694	C9ORF72, the new gene on the block, causes C9FTD/ALS: new insights provided by neuropathology. <i>Acta Neuropathologica</i> , 2011, 122, 653-655.	3.9	10
695	Modes of A β toxicity in Alzheimer's disease. <i>Cellular and Molecular Life Sciences</i> , 2011, 68, 3359-3375.	2.4	78
696	Human Genetics as a Tool to Identify Progranulin Regulators. <i>Journal of Molecular Neuroscience</i> , 2011, 45, 532-537.	1.1	4
697	The Birth and Early Evolution of the Frontotemporal Dementia (FTD) Concept. <i>Journal of Molecular Neuroscience</i> , 2011, 45, 324-329.	1.1	7
698	Clinical Aspects of Familial Forms of Frontotemporal Dementia Associated with Parkinsonism. <i>Journal of Molecular Neuroscience</i> , 2011, 45, 359-365.	1.1	17
699	Pathogenesis of the Tauopathies. <i>Journal of Molecular Neuroscience</i> , 2011, 45, 425-431.	1.1	107

#	ARTICLE	IF	CITATIONS
700	Progranulin and TDP-43: Mechanistic Links and Future Directions. <i>Journal of Molecular Neuroscience</i> , 2011, 45, 561-573.	1.1	51
701	Frontotemporal Dementia: From Mendelian Genetics Towards Genome Wide Association Studies. <i>Journal of Molecular Neuroscience</i> , 2011, 45, 500-515.	1.1	22
702	Altered microRNA expression in frontotemporal lobar degeneration with TDP-43 pathology caused by progranulin mutations. <i>BMC Genomics</i> , 2011, 12, 527.	1.2	48
703	Behavioral Genetics of Neurodegenerative Disorders. <i>Current Topics in Behavioral Neurosciences</i> , 2011, 12, 615-631.	0.8	4
704	Genetic and Clinical Features of Progranulin-Associated Frontotemporal Lobar Degeneration. <i>Archives of Neurology</i> , 2011, 68, 488.	4.9	108
705	Novel Progranulin Mutation Detected in 2 Patients With FTL. <i>Alzheimer Disease and Associated Disorders</i> , 2011, 25, 173-178.	0.6	10
706	Regulation of the alternative splicing of tau exon 10 by SC35 and Dyrk1A. <i>Nucleic Acids Research</i> , 2011, 39, 6161-6171.	6.5	84
707	Familial Semantic Dementia with P301L Mutation in the Tau Gene. <i>Dementia and Geriatric Cognitive Disorders</i> , 2011, 31, 334-340.	0.7	23
708	Functional genomic screen and network analysis reveal novel modifiers of tauopathy dissociated from tau phosphorylation. <i>Human Molecular Genetics</i> , 2011, 20, 4947-4977.	1.4	110
709	Analysis of alternative splicing associated with aging and neurodegeneration in the human brain. <i>Genome Research</i> , 2011, 21, 1572-1582.	2.4	199
710	Characterization of Prefibrillar Tau Oligomers in Vitro and in Alzheimer Disease. <i>Journal of Biological Chemistry</i> , 2011, 286, 23063-23076.	1.6	281
711	Atypical parkinsonism, parkinsonism-plus syndromes, and secondary parkinsonian disorders. , 2011, , 197-240.		2
712	Novel L284R <i>>MAPT </i>Mutation in a Family with an Autosomal Dominant Progressive Supranuclear Palsy Syndrome. <i>Neurodegenerative Diseases</i> , 2011, 8, 149-152.	0.8	47
713	Bioluminescence imaging of A β 2 deposition in bigenic mouse models of Alzheimer's disease. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2011, 108, 2528-2533.	3.3	109
714	An algorithm for genetic testing of frontotemporal lobar degeneration. <i>Neurology</i> , 2011, 76, 475-483.	1.5	70
715	<i>TMEM106B</i> regulates progranulin levels and the penetrance of FTL in <i>GRN</i> mutation carriers. <i>Neurology</i> , 2011, 76, 467-474.	1.5	211
716	Alzheimer's disease models and functional genomics"How many needles are there in the haystack?. <i>Frontiers in Physiology</i> , 2012, 3, 320.	1.3	18
717	Potential neuroprotective strategies against tauopathy. <i>Biochemical Society Transactions</i> , 2012, 40, 656-660.	1.6	4

#	ARTICLE	IF	CITATIONS
718	Distinct clinical and pathological characteristics of frontotemporal dementia associated with C9ORF72 mutations. <i>Brain</i> , 2012, 135, 693-708.	3.7	486
719	Frontotemporal Dementia: Implications for Understanding Alzheimer Disease. <i>Cold Spring Harbor Perspectives in Medicine</i> , 2012, 2, a006254-a006254.	2.9	127
720	ALS and Frontotemporal Dysfunction: A Review. <i>Neurology Research International</i> , 2012, 2012, 1-9.	0.5	57
721	The Role of Tau in Neurodegenerative Diseases and Its Potential as a Therapeutic Target. <i>Scientifica</i> , 2012, 2012, 1-20.	0.6	55
722	Progressive neuronal inclusion formation and axonal degeneration in CHMP2B mutant transgenic mice. <i>Brain</i> , 2012, 135, 819-832.	3.7	97
723	Transfection of Human Neuroblastoma Cells with Alzheimer's Disease Brain Hallmarks as a Promising Strategy to Investigate the Role of Neurosteroidogenesis in Neuroprotection. <i>BioValley Monographs</i> , 2012, , 50-59.	0.1	4
725	Assessment of psychomotor performance in Δ CaMK-II-4R tau mice: an insight into human tauopathies. <i>Future Neurology</i> , 2012, 7, 773-783.	0.9	0
726	Tau and Tauopathies. <i>Progress in Molecular Biology and Translational Science</i> , 2012, 107, 263-293.	0.9	147
727	The genetics and neuropathology of frontotemporal lobar degeneration. <i>Acta Neuropathologica</i> , 2012, 124, 353-372.	3.9	242
728	Mechanisms of disease in frontotemporal lobar degeneration: gain of function versus loss of function effects. <i>Acta Neuropathologica</i> , 2012, 124, 373-382.	3.9	89
729	Frontotemporal lobar degeneration: current knowledge and future challenges. <i>Journal of Neurology</i> , 2012, 259, 2278-2286.	1.8	36
730	Interaction of Tau Protein with Model Lipid Membranes Induces Tau Structural Compaction and Membrane Disruption. <i>Biochemistry</i> , 2012, 51, 2539-2550.	1.2	122
731	A cytoskeleton linearity measure. , 2012, , .		0
732	Biochemistry and Cell Biology of Tau Protein in Neurofibrillary Degeneration. <i>Cold Spring Harbor Perspectives in Medicine</i> , 2012, 2, a006247-a006247.	2.9	608
733	Altered expression of brain acetylcholinesterase in FTDP-17 human tau transgenic mice. <i>Neurobiology of Aging</i> , 2012, 33, 624.e23-624.e34.	1.5	24
734	New mutations in MAPT gene causing frontotemporal lobar degeneration: biochemical and structural characterization. <i>Neurobiology of Aging</i> , 2012, 33, 834.e1-834.e6.	1.5	28
735	Epidemiology and genetics of frontotemporal dementia: a door-to-door survey in Southern Italy. <i>Neurobiology of Aging</i> , 2012, 33, 2948.e1-2948.e10.	1.5	40
736	Primary Progressive Aphasia and Alzheimer's Disease: Brief History, Recent Evidence. <i>Current Neurology and Neuroscience Reports</i> , 2012, 12, 709-714.	2.0	37

#	ARTICLE	IF	CITATIONS
737	Binding of the three-repeat domain of tau to phospholipid membranes induces an aggregated-like state of the protein. <i>Biochimica Et Biophysica Acta - Biomembranes</i> , 2012, 1818, 2302-2313.	1.4	70
738	Frontotemporal Lobar Degeneration. <i>CNS Drugs</i> , 2012, 26, 841-870.	2.7	108
739	Genetics of Frontotemporal Lobar Degeneration. <i>Frontiers in Neurology</i> , 2012, 3, 52.	1.1	32
740	Advances in understanding the molecular basis of frontotemporal dementia. <i>Nature Reviews Neurology</i> , 2012, 8, 423-434.	4.9	353
741	Losing protein in the brain: The case of progranulin. <i>Brain Research</i> , 2012, 1476, 172-182.	1.1	23
742	Synaptic Dysfunction in Alzheimer's Disease. <i>Advances in Experimental Medicine and Biology</i> , 2012, 970, 573-601.	0.8	94
743	Tau Promotes Neurodegeneration via DRP1 Mislocalization In Vivo. <i>Neuron</i> , 2012, 75, 618-632.	3.8	331
744	A New Link to Mitochondrial Impairment in Tauopathies. <i>Molecular Neurobiology</i> , 2012, 46, 205-216.	1.9	109
745	Invertebrate Models of Alzheimer's Disease. <i>Journal of Alzheimer's Disease</i> , 2012, 33, 3-16.	1.2	26
746	Pooled-DNA sequencing identifies novel causative variants in PSEN1, GRN and MAPT in a clinical early-onset and familial Alzheimer's disease Ibero-American cohort. <i>Alzheimer's Research and Therapy</i> , 2012, 4, 34.	3.0	103
747	Reduced Axonal Transport and Increased Excitotoxic Retinal Ganglion Cell Degeneration in Mice Transgenic for Human Mutant P301S Tau. <i>PLoS ONE</i> , 2012, 7, e34724.	1.1	56
748	Clinical, Neuropathological, and Biochemical Characterization of the Novel Tau Mutation P332S. <i>Journal of Alzheimer's Disease</i> , 2012, 31, 741-749.	1.2	25
749	Pathology of Neurodegenerative Diseases. , 0, , .		3
750	Alzheimer's disease and related dementias. , 0, , 17-31.		0
751	Synucleinopathies and Tauopathies. , 2012, , 829-843.		5
752	Clinical phenotypes and genetic biomarkers of FTL. <i>Journal of Neural Transmission</i> , 2012, 119, 851-860.	1.4	83
753	Prevalence of frontotemporal lobar degeneration in an isolated population: the Vallecampa study. <i>Neurological Sciences</i> , 2012, 33, 899-904.	0.9	20
754	Phosphorylation of microtubule-associated protein tau by AMPK-related kinases. <i>Journal of Neurochemistry</i> , 2012, 120, 165-176.	2.1	59

#	ARTICLE	IF	CITATIONS
755	Twenty years of Alzheimer's disease-causing mutations. <i>Journal of Neurochemistry</i> , 2012, 120, 3-8.	2.1	123
756	Tau-targeted treatment strategies in Alzheimer's disease. <i>British Journal of Pharmacology</i> , 2012, 165, 1246-1259.	2.7	114
757	Dementia, Stroke, and Vascular Risk Factors; a Review. <i>International Journal of Stroke</i> , 2012, 7, 61-73.	2.9	181
758	Cellular model of Alzheimer's disease – Relevance to therapeutic testing. <i>Experimental Neurology</i> , 2012, 233, 733-739.	2.0	8
759	Selective tau tyrosine nitration in non-AD tauopathies. <i>Acta Neuropathologica</i> , 2012, 123, 119-132.	3.9	28
760	Biosensing MAPs as –roadblocks– kinesin-based functional analysis of tau protein isoforms and mutants using suspended microtubules (sMTs). <i>Lab on A Chip</i> , 2013, 13, 3217.	3.1	20
761	Development and Validation of Pedigree Classification Criteria for Frontotemporal Lobar Degeneration. <i>JAMA Neurology</i> , 2013, 70, 1411.	4.5	107
762	LRRK2 phosphorylates novel tau epitopes and promotes tauopathy. <i>Acta Neuropathologica</i> , 2013, 126, 809-827.	3.9	85
763	Genetic factors in frontotemporal dementia: A review. <i>Toxicology and Environmental Health Sciences</i> , 2013, 5, 113-130.	1.1	2
764	Parkinson's Disease – the Debate on the Clinical Phenomenology, Aetiology, Pathology and Pathogenesis. <i>Journal of Parkinson's Disease</i> , 2013, 3, 1-11.	1.5	79
765	TOC1: Characterization of a Selective Oligomeric Tau Antibody. <i>Journal of Alzheimer's Disease</i> , 2013, 37, 593-602.	1.2	50
766	Mechanisms of Granulin Deficiency: Lessons from Cellular and Animal Models. <i>Molecular Neurobiology</i> , 2013, 47, 337-360.	1.9	58
767	Glutamate Metabolism is Impaired in Transgenic Mice with Tau Hyperphosphorylation. <i>Journal of Cerebral Blood Flow and Metabolism</i> , 2013, 33, 684-691.	2.4	54
768	Amyloid Oligomers Exacerbate Tau Pathology in a Mouse Model of Tauopathy. <i>Neurodegenerative Diseases</i> , 2013, 11, 165-181.	0.8	6,857
769	Prion-Like Properties of Assembled Tau Protein. <i>Research and Perspectives in Alzheimer's Disease</i> , 2013, , 87-95.	0.1	1
770	Tau pathology and neurodegeneration. <i>Lancet Neurology</i> , The, 2013, 12, 609-622.	4.9	893
771	–Prion–Like–Templated Misfolding in Tauopathies. <i>Brain Pathology</i> , 2013, 23, 342-349.	2.1	114
772	Mechanistic Studies Unravel the Complexity Inherent in Tau Aggregation Leading to Alzheimer's Disease and the Tauopathies. <i>Biochemistry</i> , 2013, 52, 4107-4126.	1.2	51

#	ARTICLE	IF	CITATIONS
773	C9orf72 frontotemporal lobar degeneration is characterised by frequent neuronal sense and antisense RNA foci. <i>Acta Neuropathologica</i> , 2013, 126, 845-857.	3.9	289
774	Alternative polyadenylation and miR-34 family members regulate tau expression. <i>Journal of Neurochemistry</i> , 2013, 127, 739-749.	2.1	116
775	From frontotemporal lobar degeneration pathology to frontotemporal lobar degeneration biomarkers. <i>International Review of Psychiatry</i> , 2013, 25, 210-220.	1.4	13
776	Influence of Surface Groups on Poly(propylene imine) Dendrimers Antiprion Activity. <i>Biomacromolecules</i> , 2013, 14, 27-37.	2.6	45
777	Axonal Transport and Mitochondrial Dysfunction in Alzheimer's Disease. <i>Neurodegenerative Diseases</i> , 2013, 12, 111-124.	0.8	32
778	Hyperphosphorylation-Induced Tau Oligomers. <i>Frontiers in Neurology</i> , 2013, 4, 112.	1.1	80
779	Immunotherapy for the treatment of Alzheimer's disease: amyloid- β ; or tau, which is the right target?. <i>ImmunoTargets and Therapy</i> , 2014, 3, 19.	2.7	11
780	Tau Pathology is Present <i>In Vivo</i> and Develops <i>In Vitro</i> in Sensory Neurons from Human P301S Tau Transgenic Mice: A System for Screening Drugs against Tauopathies. <i>Journal of Neuroscience</i> , 2013, 33, 18175-18189.	1.7	36
781	Brain homogenates from human tauopathies induce tau inclusions in mouse brain. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2013, 110, 9535-9540.	3.3	648
782	Prostate-derived Sterile 20-like Kinases (PSKs/TAOKs) Phosphorylate Tau Protein and Are Activated in Tangle-bearing Neurons in Alzheimer Disease. <i>Journal of Biological Chemistry</i> , 2013, 288, 15418-15429.	1.6	49
783	The Genetics of Dementia. <i>Seminars in Neurology</i> , 2013, 33, 417-422.	0.5	5
784	Spreading of tau pathology in Alzheimer's disease by cell-to-cell transmission. <i>European Journal of Neuroscience</i> , 2013, 37, 1939-1948.	1.2	106
785	Isomerase Pin1 Stimulates Dephosphorylation of Tau Protein at Cyclin-dependent Kinase (Cdk5)-dependent Alzheimer Phosphorylation Sites. <i>Journal of Biological Chemistry</i> , 2013, 288, 7968-7977.	1.6	52
786	Expression of Alzheimer-Like Pathological Human Tau Induces a Behavioral Motor and Olfactory Learning Deficit in <i>Drosophila melanogaster</i> . <i>Journal of Alzheimer's Disease</i> , 2013, 37, 539-550.	1.2	31
787	Animal Models of the Sporadic Form of Alzheimer's Disease: Focus on the Disease and Not Just the Lesions. <i>Journal of Alzheimer's Disease</i> , 2013, 37, 469-474.	1.2	27
789	Neurodegenerative disorders. , 0, , 23-71.		0
790	What Renders TAU Toxic. <i>Frontiers in Neurology</i> , 2013, 4, 72.	1.1	67
791	Frontotemporal dementia and primary progressive aphasia, a review. <i>Neuropsychiatric Disease and Treatment</i> , 2014, 10, 1045.	1.0	44

#	ARTICLE	IF	CITATIONS
792	Tau Overexpression Impacts a Neuroinflammation Gene Expression Network Perturbed in Alzheimer's Disease. PLoS ONE, 2014, 9, e106050.	1.1	103
793	Early Onset Alzheimer's Disease and Oxidative Stress. Oxidative Medicine and Cellular Longevity, 2014, 2014, 1-14.	1.9	46
794	The role of extracellular Tau in the spreading of neurofibrillary pathology. Frontiers in Cellular Neuroscience, 2014, 8, 113.	1.8	130
795	Physiological and pathological phosphorylation of tau by Cdk5. Frontiers in Molecular Neuroscience, 2014, 7, 65.	1.4	194
796	Multiple System Atrophy: Genetic or Epigenetic?. Experimental Neurobiology, 2014, 23, 277-291.	0.7	28
797	Hyperphosphorylation of Tau Protein in Down's Dementia and Alzheimer's Disease: Methylation and Implications in Prevention and Therapy. , 2014, 04, .		5
798	Tau-Mediated NMDA Receptor Impairment Underlies Dysfunction of a Selectively Vulnerable Network in a Mouse Model of Frontotemporal Dementia. Journal of Neuroscience, 2014, 34, 16482-16495.	1.7	60
799	Specific Calpain Inhibition by Calpastatin Prevents Tauopathy and Neurodegeneration and Restores Normal Lifespan in Tau P301L Mice. Journal of Neuroscience, 2014, 34, 9222-9234.	1.7	87
800	Alpha-synuclein and tau: teammates in neurodegeneration?. Molecular Neurodegeneration, 2014, 9, 43.	4.4	216
801	Antisense-mediated Exon Skipping Decreases Tau Protein Expression: A Potential Therapy For Tauopathies. Molecular Therapy - Nucleic Acids, 2014, 3, e180.	2.3	54
802	Targets and Small Molecules Against Tauopathies. Part 1: From Genes to Soluble, Aggregation-Prone Tau Proteins. , 2014, , 643-715.		0
803	Use of Caenorhabditis elegans as a model to study Alzheimer's disease and other neurodegenerative diseases. Frontiers in Genetics, 2014, 5, 279.	1.1	242
804	Genetics in Degenerative Dementia. Alzheimer Disease and Associated Disorders, 2014, 28, 199-205.	0.6	15
806	Intercellular transfer of tau aggregates and spreading of tau pathology: Implications for therapeutic strategies. Neuropharmacology, 2014, 76, 9-15.	2.0	58
807	Novel mutation in MAPT exon 13 (p.N410H) causes corticobasal degeneration. Acta Neuropathologica, 2014, 127, 271-282.	3.9	66
808	A novel in vivo model of tau propagation with rapid and progressive neurofibrillary tangle pathology: the pattern of spread is determined by connectivity, not proximity. Acta Neuropathologica, 2014, 127, 667-683.	3.9	390
809	Tau promotes neurodegeneration through global chromatin relaxation. Nature Neuroscience, 2014, 17, 357-366.	7.1	370
810	Severe amygdala dysfunction in a MAPT transgenic mouse model of frontotemporal dementia. Neurobiology of Aging, 2014, 35, 1769-1777.	1.5	48

#	ARTICLE	IF	CITATIONS
811	Human stem cell models of neurodegeneration: a novel approach to study mechanisms of disease development. <i>Acta Neuropathologica</i> , 2014, 127, 151-173.	3.9	44
812	Microtubule-associated protein tau as a therapeutic target in Alzheimer's disease. <i>Expert Opinion on Therapeutic Targets</i> , 2014, 18, 307-318.	1.5	65
813	Emerging Therapeutics for Alzheimer's Disease. <i>Annual Review of Pharmacology and Toxicology</i> , 2014, 54, 381-405.	4.2	76
814	Necrotic Cell Death in <i>Caenorhabditis elegans</i> . <i>Methods in Enzymology</i> , 2014, 545, 127-155.	0.4	18
815	Development of mouse fibroblast cell line expressing human tau protein and evaluation of tau-dependent cytotoxicity. <i>Biochemistry (Moscow) Supplement Series A: Membrane and Cell Biology</i> , 2014, 8, 232-239.	0.3	2
816	Molecular genetics and antisocial behavior: Where do we stand?. <i>Experimental Biology and Medicine</i> , 2014, 239, 1514-1523.	1.1	67
817	Alzheimer's Disease, Anesthesia, and Surgery: A Clinically Focused Review. <i>Journal of Cardiothoracic and Vascular Anesthesia</i> , 2014, 28, 1609-1623.	0.6	39
818	Clinicopathologic assessment and imaging of tauopathies in neurodegenerative dementias. <i>Alzheimer's Research and Therapy</i> , 2014, 6, 1.	3.0	156
819	Different mutations at V363 MAPT codon are associated with atypical clinical phenotypes and show unusual structural and functional features. <i>Neurobiology of Aging</i> , 2014, 35, 408-417.	1.5	36
820	March separate, strike together - Role of phosphorylated TAU in mitochondrial dysfunction in Alzheimer's disease. <i>Biochimica Et Biophysica Acta - Molecular Basis of Disease</i> , 2014, 1842, 1258-1266.	1.8	92
821	Fractalkine signaling and Tau hyper-phosphorylation are associated with autophagic alterations in lentiviral Tau and A β 1-42 gene transfer models. <i>Experimental Neurology</i> , 2014, 251, 127-138.	2.0	13
822	Pathogenesis/genetics of frontotemporal dementia and how it relates to ALS. <i>Experimental Neurology</i> , 2014, 262, 84-90.	2.0	78
823	C9orf72; abnormal RNA expression is the key. <i>Experimental Neurology</i> , 2014, 262, 102-110.	2.0	15
824	Early-onset cognitive deficits and axonal transport dysfunction in P301S mutant tau transgenic mice. <i>Neuroscience Research</i> , 2014, 80, 76-85.	1.0	17
825	Identification of structural determinants on tau protein essential for its pathological function: novel therapeutic target for tau immunotherapy in Alzheimer's disease. <i>Alzheimer's Research and Therapy</i> , 2014, 6, 45.	3.0	96
826	A Mutation in the 5' UTR of GRN Gene Associated with Frontotemporal Lobar Degeneration: Phenotypic Variability and Possible Pathogenetic Mechanisms. <i>Journal of Alzheimer's Disease</i> , 2014, 42, 939-947.	1.2	12
827	Anti-tau antibody reduces insoluble tau and decreases brain atrophy. <i>Annals of Clinical and Translational Neurology</i> , 2015, 2, 278-288.	1.7	145
828	Toxic tau oligomer formation blocked by capping of cysteine residues with 1,2-dihydroxybenzene groups. <i>Nature Communications</i> , 2015, 6, 10216.	5.8	94

#	ARTICLE	IF	CITATIONS
829	Glial Tau Pathology in Tauopathies: Functional Consequences. <i>Journal of Experimental Neuroscience</i> , 2015, 9s2, JEN.S25515.	2.3	69
830	Insight into Atomic Resolution of the Cross-Seedling between Tau/Mutated Tau and Amyloid β in Neurodegenerative Diseases. <i>Israel Journal of Chemistry</i> , 2015, 55, 628-636.	1.0	6
831	Phenotypic Heterogeneity of Monogenic Frontotemporal Dementia. <i>Frontiers in Aging Neuroscience</i> , 2015, 7, 171.	1.7	90
832	Imaging Multimodalities for Dissecting Alzheimer's Disease: Advanced Technologies of Positron Emission Tomography and Fluorescence Imaging. <i>Frontiers in Neuroscience</i> , 2015, 9, 482.	1.4	26
834	Telling the Story of Frontotemporal Dementia by Bibliometric Analysis. <i>Journal of Alzheimer's Disease</i> , 2015, 48, 703-709.	1.2	12
835	Genetics of Progressive Supranuclear Palsy. <i>Journal of Movement Disorders</i> , 2015, 8, 122-129.	0.7	60
836	Developmental regulation of tau splicing is disrupted in stem cell-derived neurons from frontotemporal dementia patients with the 10 + 16 splice-site mutation in MAPT. <i>Human Molecular Genetics</i> , 2015, 24, 5260-5269.	1.4	116
837	Tau deposition drives neuropathological, inflammatory and behavioral abnormalities independently of neuronal loss in a novel mouse model. <i>Human Molecular Genetics</i> , 2015, 24, 6198-6212.	1.4	52
838	Ion Channel Formation by Tau Protein: Implications for Alzheimer's Disease and Tauopathies. <i>Biochemistry</i> , 2015, 54, 7320-7325.	1.2	41
839	A Novel Tau Mutation in Exon 12, p.Q336H, Causes Hereditary Pick Disease. <i>Journal of Neuropathology and Experimental Neurology</i> , 2015, 74, 1042-1052.	0.9	27
840	Tau missorting and spastin-induced microtubule disruption in neurodegeneration: Alzheimer Disease and Hereditary Spastic Paraplegia. <i>Molecular Neurodegeneration</i> , 2015, 10, 68.	4.4	69
841	Conformation Determines the Seeding Potencies of Native and Recombinant Tau Aggregates. <i>Journal of Biological Chemistry</i> , 2015, 290, 1049-1065.	1.6	225
842	Invited review: Frontotemporal dementia caused by <i>microtubule-associated protein tau</i> gene (<i>MAPT</i>) mutations: a chameleon for neuropathology and neuroimaging. <i>Neuropathology and Applied Neurobiology</i> , 2015, 41, 24-46.	1.8	360
843	Inflammatory molecules in Frontotemporal Dementia: Cerebrospinal fluid signature of progranulin mutation carriers. <i>Brain, Behavior, and Immunity</i> , 2015, 49, 182-187.	2.0	51
844	Alzheimer's and Parkinson's diseases: The prion concept in relation to assembled $A\beta$, tau, and α -synuclein. <i>Science</i> , 2015, 349, 1255-1255.	6.0	753
845	Amyloid cascade hypothesis: Pathogenesis and therapeutic strategies in Alzheimer's disease. <i>Neuropeptides</i> , 2015, 52, 1-18.	0.9	405
846	Genetics of Parkinson Disease and Related Diseases. , 2015, , 769-778.		1
847	Increasing progranulin levels and blockade of the ERK1/2 pathway: Upstream and downstream strategies for the treatment of progranulin deficient frontotemporal dementia. <i>European Neuropsychopharmacology</i> , 2015, 25, 386-403.	0.3	20

#	ARTICLE	IF	CITATIONS
848	Impaired retrograde transport by the Dynein/Dynactin complex contributes to Tau-induced toxicity. <i>Human Molecular Genetics</i> , 2015, 24, 3623-3637.	1.4	58
849	Differential induction and spread of tau pathology in young PS19 tau transgenic mice following intracerebral injections of pathological tau from Alzheimer's disease or corticobasal degeneration brains. <i>Acta Neuropathologica</i> , 2015, 129, 221-237.	3.9	211
850	Tauopathy Mouse Models. , 2015, , 849-855.		0
851	Protein Misfolding, Neurodegeneration and Tau. , 2015, , 1-38.		0
852	FTD and ALS"translating mouse studies into clinical trials. <i>Nature Reviews Neurology</i> , 2015, 11, 360-366.	4.9	64
853	Structural determinants for alternative splicing regulation of the MAPT pre-mRNA. <i>RNA Biology</i> , 2015, 12, 330-342.	1.5	21
854	Genetics of Frontotemporal Dementia. , 2015, , 75-105.		0
855	Tau Protein. , 2015, , 857-874.		2
856	Invited review: Prion-like transmission and spreading of tau pathology. <i>Neuropathology and Applied Neurobiology</i> , 2015, 41, 47-58.	1.8	130
857	Connecting the dots between tau dysfunction and neurodegeneration. <i>Trends in Cell Biology</i> , 2015, 25, 46-53.	3.6	108
858	Primary progressive aphasia: conceptual evolution and challenges. <i>Neuroscience and Neuroeconomics</i> , 2016, , 9.	0.9	7
859	Tau Protein Hyperphosphorylation and Aggregation in Alzheimer's Disease and Other Tauopathies, and Possible Neuroprotective Strategies. <i>Biomolecules</i> , 2016, 6, 6.	1.8	503
860	Molecular Mechanisms in the Pathogenesis of Alzheimer's disease and Tauopathies-Prion-Like Seeded Aggregation and Phosphorylation. <i>Biomolecules</i> , 2016, 6, 24.	1.8	53
861	Review: Induced pluripotent stem cell models of frontotemporal dementia. <i>Neuropathology and Applied Neurobiology</i> , 2016, 42, 497-520.	1.8	8
862	An autopsied case of unclassifiable sporadic four-repeat tauopathy presenting with parkinsonism and speech disturbances. <i>Neuropathology</i> , 2016, 36, 295-304.	0.7	3
863	Role of Niemann-Pick Type C Disease Mutations in Dementia. <i>Journal of Alzheimer's Disease</i> , 2016, 55, 1249-1259.	1.2	24
866	Genetics of Frontotemporal Lobar Degeneration: From the Bench to the Clinic. <i>Journal of Alzheimer's Disease</i> , 2016, 52, 1157-1176.	1.2	6
867	Genetic Counseling and Testing for Alzheimer's Disease and Frontotemporal Lobar Degeneration: An Italian Consensus Protocol. <i>Journal of Alzheimer's Disease</i> , 2016, 51, 277-291.	1.2	18

#	ARTICLE	IF	CITATIONS
868	Microtubule-Stabilizing Agents for Alzheimer's and Other Tauopathies. Topics in Medicinal Chemistry, 2016, , 159-179.	0.4	5
869	Tau: From research to clinical development. Alzheimer's and Dementia, 2016, 12, 1033-1039.	0.4	117
870	The cytoskeleton as a novel therapeutic target for old neurodegenerative disorders. Progress in Neurobiology, 2016, 141, 61-82.	2.8	92
871	Molecular mechanism of prion-like tau-induced neurodegeneration. Alzheimer's and Dementia, 2016, 12, 1090-1097.	0.4	53
872	Impaired protein degradation in FTLN and related disorders. Ageing Research Reviews, 2016, 32, 122-139.	5.0	58
873	The ordered assembly of tau is the gain-of-toxic function that causes human tauopathies. Alzheimer's and Dementia, 2016, 12, 1040-1050.	0.4	54
874	Tau physiology and pathomechanisms in frontotemporal lobar degeneration. Journal of Neurochemistry, 2016, 138, 71-94.	2.1	85
875	Common Molecular Pathways in Amyotrophic Lateral Sclerosis and Frontotemporal Dementia. Trends in Molecular Medicine, 2016, 22, 769-783.	3.5	103
876	Prion-like propagation as a pathogenic principle in frontotemporal dementia. Journal of Neurochemistry, 2016, 138, 163-183.	2.1	54
877	Genetics of <scp>FTLD</scp>: overview and what else we can expect from genetic studies. Journal of Neurochemistry, 2016, 138, 32-53.	2.1	118
878	Charting Frontotemporal Dementia: From Genes to Networks. Journal of Neuroimaging, 2016, 26, 16-27.	1.0	9
879	Tau prions from Alzheimer's disease and chronic traumatic encephalopathy patients propagate in cultured cells. Proceedings of the National Academy of Sciences of the United States of America, 2016, 113, E8187-E8196.	3.3	141
880	Genetics of Frontotemporal Dementia. Current Neurology and Neuroscience Reports, 2016, 16, 107.	2.0	100
881	Tau and tauopathies. Brain Research Bulletin, 2016, 126, 238-292.	1.4	444
882	Molecular Pathways Leading to the Clinical Phenomenology of Frontotemporal Dementia. , 2016, , 533-546.		1
883	Pathophysiology and animal models of frontotemporal dementia. , 0, , 197-210.		0
884	Missense mutations in progranulin gene associated with frontotemporal lobar degeneration: study of pathogenetic features. Neurobiology of Aging, 2016, 38, 215.e1-215.e12.	1.5	16
885	The Abundance of Nonphosphorylated Tau in Mouse and Human Tauopathy Brains Revealed by the Use of Phos-Tag Method. American Journal of Pathology, 2016, 186, 398-409.	1.9	20

#	ARTICLE	IF	CITATIONS
886	Aging-related tau astroglipathy (ARTAG): harmonized evaluation strategy. <i>Acta Neuropathologica</i> , 2016, 131, 87-102.	3.9	380
887	Tau and neurodegenerative disease: the story so far. <i>Nature Reviews Neurology</i> , 2016, 12, 15-27.	4.9	603
888	Molecular Pathways in Alzheimer's Disease and Cognitive Function. , 2016, , 135-167.		1
889	Obesity, diabetes, and leptin resistance promote tau pathology in a mouse model of disease. <i>Neuroscience</i> , 2016, 315, 162-174.	1.1	70
890	Glycation alter the process of Tau phosphorylation to change Tau isoforms aggregation property. <i>Biochimica Et Biophysica Acta - Molecular Basis of Disease</i> , 2016, 1862, 192-201.	1.8	40
891	Repetitive head trauma, chronic traumatic encephalopathy and tau: Challenges in translating from mice to men. <i>Experimental Neurology</i> , 2016, 275, 389-404.	2.0	75
892	Reduced number of axonal mitochondria and tau hypophosphorylation in mouse P301L tau knockin neurons. <i>Neurobiology of Disease</i> , 2016, 85, 1-10.	2.1	57
893	Protein aggregation and neurodegeneration in prototypical neurodegenerative diseases: Examples of amyloidopathies, tauopathies and synucleinopathies. <i>Progress in Neurobiology</i> , 2017, 155, 171-193.	2.8	137
894	Unusually long duration and delayed penetrance in a family with FTD and mutation in <i>MAPT</i> (V337M). <i>American Journal of Medical Genetics Part B: Neuropsychiatric Genetics</i> , 2017, 174, 70-74.	1.1	12
895	Frontotemporal dementia with the V337M <i>MAPT</i> mutation. <i>Neurology</i> , 2017, 88, 758-766.	1.5	76
896	Rab7A regulates tau secretion. <i>Journal of Neurochemistry</i> , 2017, 141, 592-605.	2.1	54
897	Increased 4R tau expression and behavioural changes in a novel <i>MAPT</i> -N296H genomic mouse model of tauopathy. <i>Scientific Reports</i> , 2017, 7, 43198.	1.6	13
898	Frontotemporal Dementia. <i>Neurologic Clinics</i> , 2017, 35, 339-374.	0.8	286
899	Preclinical models of Alzheimer's disease for identification and preclinical validation of therapeutic targets: from fine-tuning strategies for validated targets to new venues for therapy. , 2017, , 115-156.		2
900	Frontotemporal dementia. , 2017, , 199-249.		1
901	The novel <i>PSEN1</i> M84V mutation associated to frontal dysexecutive syndrome, spastic paraparesis, and cerebellar atrophy in a dominant Alzheimer's disease family. <i>Neurobiology of Aging</i> , 2017, 56, 213.e7-213.e12.	1.5	19
902	A Brief Overview of Tauopathy: Causes, Consequences, and Therapeutic Strategies. <i>Trends in Pharmacological Sciences</i> , 2017, 38, 637-648.	4.0	164
903	Propagation of Tau aggregates. <i>Molecular Brain</i> , 2017, 10, 18.	1.3	154

#	ARTICLE	IF	CITATIONS
904	Modeling tau pathology in human stem cell derived neurons. <i>Brain Pathology</i> , 2017, 27, 525-529.	2.1	11
905	Roles of tau protein in health and disease. <i>Acta Neuropathologica</i> , 2017, 133, 665-704.	3.9	639
906	Molecular Genetics of Neurodegenerative Dementias. <i>Cold Spring Harbor Perspectives in Biology</i> , 2017, 9, a023705.	2.3	51
907	The Prion-Like Behavior of Assembled Tau in Transgenic Mice. <i>Cold Spring Harbor Perspectives in Medicine</i> , 2017, 7, a024372.	2.9	28
908	Protein Deimination in Protein Misfolding Disorders: Modeled in Human Induced Pluripotent Stem Cells (iPSCs). , 2017, , 227-239.		1
909	Human TAUP301L overexpression results in TAU hyperphosphorylation without neurofibrillary tangles in adult zebrafish brain. <i>Scientific Reports</i> , 2017, 7, 12959.	1.6	29
910	Amyloidogenesis of Tau protein. <i>Protein Science</i> , 2017, 26, 2126-2150.	3.1	102
912	The Study of Postmortem Human Synaptosomes for Understanding Alzheimer's Disease and Other Neurological Disorders: A Review. <i>Neurology and Therapy</i> , 2017, 6, 57-68.	1.4	54
913	Propagation of Tau Aggregates and Neurodegeneration. <i>Annual Review of Neuroscience</i> , 2017, 40, 189-210.	5.0	453
914	Alzheimer's Disease: Insights from Genetic Mouse Models and Current Advances in Human iPSC-Derived Neurons. <i>Advances in Neurobiology</i> , 2017, 15, 3-29.	1.3	4
915	FTDP ¹⁷ with Pick body-like inclusions associated with a novel tau mutation, p.E372G. <i>Brain Pathology</i> , 2017, 27, 612-626.	2.1	11
916	The Heritability of Frontotemporal Lobar Degeneration: Validation of Pedigree Classification Criteria in a Northern Italy Cohort. <i>Journal of Alzheimer's Disease</i> , 2017, 61, 753-760.	1.2	26
917	Animal models of dementia. , 0, , 77-93.		0
918	Cerebrospinal Fluid Biomarkers in Alzheimer's Disease "From Brain Starch to Bench and Bedside. <i>Diagnostics</i> , 2017, 7, 42.	1.3	19
919	Frontotemporal dementia. <i>Handbook of Clinical Neurology</i> / Edited By P J Vinken and G W Bruyn, 2018, 148, 409-430.	1.0	51
920	Progress and Challenges in Frontotemporal Dementia Research: A 20-Year Review. <i>Journal of Alzheimer's Disease</i> , 2018, 62, 1467-1480.	1.2	47
921	Recent developments with tau-based drug discovery. <i>Expert Opinion on Drug Discovery</i> , 2018, 13, 399-410.	2.5	35
922	Targeting Alzheimer's disease with gene and cell therapies. <i>Journal of Internal Medicine</i> , 2018, 284, 2-36.	2.7	42

#	ARTICLE	IF	CITATIONS
923	Novel GRN Mutations in Alzheimer's Disease and Frontotemporal Lobar Degeneration. <i>Journal of Alzheimer's Disease</i> , 2018, 62, 1683-1689.	1.2	12
924	Our Tau Tales from Normal to Pathological Behavior. <i>Journal of Alzheimer's Disease</i> , 2018, 64, S507-S516.	1.2	7
925	Clinical variability and onset age modifiers in an extended Belgian GRN founder family. <i>Neurobiology of Aging</i> , 2018, 67, 84-94.	1.5	17
926	Shedding light on aberrant interactions – a review of modern tools for studying protein aggregates. <i>FEBS Journal</i> , 2018, 285, 3604-3630.	2.2	10
927	Familial and sporadic chronic progressive degenerative parietal ataxia. <i>Journal of the Neurological Sciences</i> , 2018, 387, 70-74.	0.3	1
928	Tauopathies. <i>Handbook of Clinical Neurology / Edited By P J Vinken and G W Bruyn</i> , 2018, 145, 355-368.	1.0	156
929	Retiring the term FTDP-17 as MAPT mutations are genetic forms of sporadic frontotemporal tauopathies. <i>Brain</i> , 2018, 141, 521-534.	3.7	114
930	Extended FTL D pedigree segregating a Belgian GRN-null mutation: neuropathological heterogeneity in one family. <i>Alzheimer's Research and Therapy</i> , 2018, 10, 7.	3.0	10
931	Prion-like Spreading in Tauopathies. <i>Biological Psychiatry</i> , 2018, 83, 337-346.	0.7	70
932	Genetic polymorphisms associated with the risk of concussion in 1056 college athletes: a multicentre prospective cohort study. <i>British Journal of Sports Medicine</i> , 2018, 52, 192-198.	3.1	24
933	Neurodegeneration and the ordered assembly of α -synuclein. <i>Cell and Tissue Research</i> , 2018, 373, 137-148.	1.5	79
934	A Conserved Cytoskeletal Signaling Cascade Mediates Neurotoxicity of FTDP-17 Tau Mutations <i>In Vivo</i> . <i>Journal of Neuroscience</i> , 2018, 38, 108-119.	1.7	35
935	Distinct Conformers of Assembled Tau in Alzheimer's and Pick's Diseases. <i>Cold Spring Harbor Symposia on Quantitative Biology</i> , 2018, 83, 163-171.	2.0	53
937	Ten Years of Tau-Targeted Immunotherapy: The Path Walked and the Roads Ahead. <i>Frontiers in Neuroscience</i> , 2018, 12, 798.	1.4	67
938	Drosophila Models of Sporadic Parkinson's Disease. <i>International Journal of Molecular Sciences</i> , 2018, 19, 3343.	1.8	37
939	AADVAC1, AN ACTIVE IMMUNOTHERAPY FOR ALZHEIMER'S DISEASE AND NON ALZHEIMER TAUOPATHIES: AN OVERVIEW OF PRECLINICAL AND CLINICAL DEVELOPMENT. <i>Journal of Prevention of Alzheimer's Disease</i> , 2019, 6, 1-7.	1.5	44
940	Hyperphosphorylation of Tau Associates With Changes in Its Function Beyond Microtubule Stability. <i>Frontiers in Cellular Neuroscience</i> , 2018, 12, 338.	1.8	151
941	Genotype-phenotype links in frontotemporal lobar degeneration. <i>Nature Reviews Neurology</i> , 2018, 14, 363-378.	4.9	68

#	ARTICLE	IF	CITATIONS
942	Tau filaments in neurodegenerative diseases. FEBS Letters, 2018, 592, 2383-2391.	1.3	100
943	Secretion of full-length Tau or Tau fragments in cell culture models. Propagation of Tau in vivo and in vitro. Biomolecular Concepts, 2018, 9, 1-11.	1.0	14
944	Neurofibrillary tangles mediated human neuronal tauopathies: insights from fly models. Journal of Genetics, 2018, 97, 783-793.	0.4	6
945	Reconsideration of Amyloid Hypothesis and Tau Hypothesis in Alzheimer's Disease. Frontiers in Neuroscience, 2018, 12, 25.	1.4	591
946	Phospho-Tau Bar Code: Analysis of Phosphoisotypes of Tau and Its Application to Tauopathy. Frontiers in Neuroscience, 2018, 12, 44.	1.4	82
947	Vesicular Axonal Transport is Modified In Vivo by Tau Deletion or Overexpression in Drosophila. International Journal of Molecular Sciences, 2018, 19, 744.	1.8	15
948	Recent Insights on Alzheimer's Disease Originating from Yeast Models. International Journal of Molecular Sciences, 2018, 19, 1947.	1.8	29
949	Glycogen synthase kinase-3 and alternative splicing. Wiley Interdisciplinary Reviews RNA, 2018, 9, e1501.	3.2	20
950	Tau Conformation as a Target for Disease-Modifying Therapy: The Role of Truncation. Journal of Alzheimer's Disease, 2018, 64, S535-S546.	1.2	29
951	The genetics of dementia with Lewy bodies. Handbook of Clinical Neurology / Edited By P J Vinken and G W Bruyn, 2018, 148, 431-440.	1.0	1
952	Clinical and Genetic Study of the First Japanese FTDP-17 Patient with a Mutation of +3 in Intron 10 in the <i>MAPT</i> Gene. Internal Medicine, 2019, 58, 2397-2400.	0.3	2
953	Novel GRN mutations in Koreans with Alzheimer's disease. Molecular and Cellular Toxicology, 2019, 15, 345-352.	0.8	3
954	Novel P397S <i>MAPT</i> variant associated with late onset and slow progressive frontotemporal dementia. Annals of Clinical and Translational Neurology, 2019, 6, 1559-1565.	1.7	6
955	Frontrunner in Translation: Progressive Supranuclear Palsy. Frontiers in Neurology, 2019, 10, 1125.	1.1	19
956	Loss of tau and Fyn reduces compensatory effects of MAP2 for tau and reveals a Fyn-independent effect of tau on calcium. Journal of Neuroscience Research, 2019, 97, 1393-1413.	1.3	13
957	<i>MAPT</i> p.V363I mutation. Neurology: Genetics, 2019, 5, e347.	0.9	10
958	Heparin-induced tau filaments are polymorphic and differ from those in Alzheimer's and Pick's diseases. ELife, 2019, 8, .	2.8	309
959	Constitutive XBP-1s-mediated activation of the endoplasmic reticulum unfolded protein response protects against pathological tau. Nature Communications, 2019, 10, 4443.	5.8	47

#	ARTICLE	IF	CITATIONS
960	Pathological Progression Induced by the Frontotemporal Dementia-Associated R406W Tau Mutation in Patient-Derived iPSCs. <i>Stem Cell Reports</i> , 2019, 13, 684-699.	2.3	46
961	Tauopathy: A common mechanism for neurodegeneration and brain aging. <i>Mechanisms of Ageing and Development</i> , 2019, 178, 72-79.	2.2	83
962	Cellular and regional vulnerability in frontotemporal tauopathies. <i>Acta Neuropathologica</i> , 2019, 138, 705-727.	3.9	49
963	CSF placental growth factor "a novel candidate biomarker of frontotemporal dementia. <i>Annals of Clinical and Translational Neurology</i> , 2019, 6, 863-872.	1.7	9
964	The role of APOE in transgenic mouse models of AD. <i>Neuroscience Letters</i> , 2019, 707, 134285.	1.0	37
965	Genome Wide Association Study and Next Generation Sequencing: A Glimmer of Light Toward New Possible Horizons in Frontotemporal Dementia Research. <i>Frontiers in Neuroscience</i> , 2019, 13, 506.	1.4	23
966	Amyotrophic Lateral Sclerosis-associated GGGGCC repeat expansion promotes Tau phosphorylation and toxicity. <i>Neurobiology of Disease</i> , 2019, 130, 104493.	2.1	8
967	Aaron Klug and the study of Alzheimer's disease. <i>Alzheimer's and Dementia</i> , 2019, 15, 859-861.	0.4	0
968	The complexity of tau in Alzheimer's disease. <i>Neuroscience Letters</i> , 2019, 705, 183-194.	1.0	200
969	Neuropathological changes and cognitive deficits in rats transgenic for human mutant tau recapitulate human tauopathy. <i>Neurobiology of Disease</i> , 2019, 127, 323-338.	2.1	14
970	<i>In vivo</i> imaging reveals reduced activity of neuronal circuits in a mouse tauopathy model. <i>Brain</i> , 2019, 142, 1051-1062.	3.7	39
971	Assembly of transgenic human P301S Tau is necessary for neurodegeneration in murine spinal cord. <i>Acta Neuropathologica Communications</i> , 2019, 7, 44.	2.4	23
972	The Effectiveness of Vitamin E Treatment in Alzheimer's Disease. <i>International Journal of Molecular Sciences</i> , 2019, 20, 879.	1.8	100
973	Tau and TDP-43 proteinopathies: kindred pathologic cascades and genetic pleiotropy. <i>Laboratory Investigation</i> , 2019, 99, 993-1007.	1.7	60
974	MAPT mutations, tauopathy, and mechanisms of neurodegeneration. <i>Laboratory Investigation</i> , 2019, 99, 912-928.	1.7	190
975	Recent Advances in the Genetics of Frontotemporal Dementia. <i>Current Genetic Medicine Reports</i> , 2019, 7, 41-52.	1.9	41
976	Heritability in frontotemporal tauopathies. <i>Alzheimer's and Dementia: Diagnosis, Assessment and Disease Monitoring</i> , 2019, 11, 115-124.	1.2	17
977	Activity of the poly(A) binding protein MSUT2 determines susceptibility to pathological tau in the mammalian brain. <i>Science Translational Medicine</i> , 2019, 11, .	5.8	30

#	ARTICLE	IF	CITATIONS
978	Parkinsonism in frontotemporal dementias. <i>International Review of Neurobiology</i> , 2019, 149, 249-275.	0.9	24
979	It's all about tau. <i>Progress in Neurobiology</i> , 2019, 175, 54-76.	2.8	134
980	Molecular Pathogenesis of the Tauopathies. <i>Annual Review of Pathology: Mechanisms of Disease</i> , 2019, 14, 239-261.	9.6	161
981	Tau Abnormalities and the Potential Therapy in Alzheimer's Disease. <i>Journal of Alzheimer's Disease</i> , 2019, 67, 13-33.	1.2	18
982	Small molecule targeting of RNA structures in neurological disorders. <i>Annals of the New York Academy of Sciences</i> , 2020, 1471, 57-71.	1.8	18
983	Propagation of Tau Pathology: Integrating Insights From Postmortem and In Vivo Studies. <i>Biological Psychiatry</i> , 2020, 87, 808-818.	0.7	50
984	Bidirectional relationship between sleep and Alzheimer's disease: role of amyloid, tau, and other factors. <i>Neuropsychopharmacology</i> , 2020, 45, 104-120.	2.8	280
985	Two pathologically confirmed cases of novel mutations in the MAPT gene causing frontotemporal dementia. <i>Neurobiology of Aging</i> , 2020, 87, 141.e15-141.e20.	1.5	3
986	Integrated analysis of the aging brain transcriptome and proteome in tauopathy. <i>Molecular Neurodegeneration</i> , 2020, 15, 56.	4.4	22
987	Neuroimaging in genetic frontotemporal dementia and amyotrophic lateral sclerosis. <i>Neurobiology of Disease</i> , 2020, 145, 105063.	2.1	23
988	Tau at the interface between neurodegeneration and neuroinflammation. <i>Genes and Immunity</i> , 2020, 21, 288-300.	2.2	33
989	Fyn depletion ameliorates tauP301L-induced neuropathology. <i>Acta Neuropathologica Communications</i> , 2020, 8, 108.	2.4	17
990	Tau PTM Profiles Identify Patient Heterogeneity and Stages of Alzheimer's Disease. <i>Cell</i> , 2020, 183, 1699-1713.e13.	13.5	354
991	An Increased Plasma Level of ApoCIII-Rich Electronegative High-Density Lipoprotein May Contribute to Cognitive Impairment in Alzheimer's Disease. <i>Biomedicines</i> , 2020, 8, 542.	1.4	6
992	Tau Protein in Lung Smooth Muscle Cells. <i>Journal of Respiration</i> , 2020, 1, 30-39.	0.4	4
993	Tau Filament Self-Assembly and Structure: Tau as a Therapeutic Target. <i>Frontiers in Neurology</i> , 2020, 11, 590754.	1.1	32
994	Tau Protein and Its Role in Blood-Brain Barrier Dysfunction. <i>Frontiers in Molecular Neuroscience</i> , 2020, 13, 570045.	1.4	77
995	Modelling frontotemporal dementia using patient-derived induced pluripotent stem cells. <i>Molecular and Cellular Neurosciences</i> , 2020, 109, 103553.	1.0	19

#	ARTICLE	IF	CITATIONS
996	Tau proteinopathies and the prion concept. <i>Progress in Molecular Biology and Translational Science</i> , 2020, 175, 239-259.	0.9	20
997	Untangling the origin and function of granulovacuolar degeneration bodies in neurodegenerative proteinopathies. <i>Acta Neuropathologica Communications</i> , 2020, 8, 153.	2.4	10
998	The Q336H MAPT Mutation Linked to Pickâ€™s Disease Leads to Increased Binding of Tau to the Microtubule Network via Altered Conformational and Phosphorylation Effects. <i>Frontiers in Molecular Neuroscience</i> , 2020, 13, 569395.	1.4	5
999	Targeting Mitophagy in Alzheimerâ€™s Disease. <i>Journal of Alzheimer's Disease</i> , 2020, 78, 1273-1297.	1.2	6
1000	Comparison of Common and Disease-Specific Post-translational Modifications of Pathological Tau Associated With a Wide Range of Tauopathies. <i>Frontiers in Neuroscience</i> , 2020, 14, 581936.	1.4	47
1001	Resurrecting the Mysteries of Big Tau. <i>Trends in Neurosciences</i> , 2020, 43, 493-504.	4.2	54
1002	Targeting tau: Clinical trials and novel therapeutic approaches. <i>Neuroscience Letters</i> , 2020, 731, 134919.	1.0	63
1003	Cryo-EM structures of tau filaments. <i>Current Opinion in Structural Biology</i> , 2020, 64, 17-25.	2.6	165
1004	Alzheimer's disease pathology in APOE transgenic mouse models: The Who, What, When, Where, Why, and How. <i>Neurobiology of Disease</i> , 2020, 139, 104811.	2.1	44
1005	Synergistic toxicity between tau and amyloid drives neuronal dysfunction and neurodegeneration in transgenic <i>C. elegans</i> . <i>Human Molecular Genetics</i> , 2020, 29, 495-505.	1.4	52
1006	Altered Levels and Isoforms of Tau and Nuclear Membrane Invaginations in Huntingtonâ€™s Disease. <i>Frontiers in Cellular Neuroscience</i> , 2019, 13, 574.	1.8	27
1007	Disease-Associated Mutant Tau Prevents Circadian Changes in the Cytoskeleton of Central Pacemaker Neurons. <i>Frontiers in Neuroscience</i> , 2020, 14, 232.	1.4	10
1008	Dysregulation of Exosome Cargo by Mutant Tau Expressed in Human-induced Pluripotent Stem Cell (iPSC) Neurons Revealed by Proteomics Analyses. <i>Molecular and Cellular Proteomics</i> , 2020, 19, 1017-1034.	2.5	34
1009	Maturation and phenotype of pathophysiological neuronal excitability of human cells in tau-related dementia. <i>Journal of Cell Science</i> , 2020, 133, .	1.2	17
1010	Modelling neurodegenerative disease using brain organoids. <i>Seminars in Cell and Developmental Biology</i> , 2021, 111, 60-66.	2.3	25
1011	Knockinâ€™ on heavenâ€™s door: Molecular mechanisms of neuronal tau uptake. <i>Journal of Neurochemistry</i> , 2021, 156, 563-588.	2.1	14
1012	Brain volumetric deficits in <i>MAPT</i> mutation carriers: a multisite study. <i>Annals of Clinical and Translational Neurology</i> , 2021, 8, 95-110.	1.7	21
1013	Lysosomal Dysfunction and Other Pathomechanisms in FTLD: Evidence from Progranulin Genetics and Biology. <i>Advances in Experimental Medicine and Biology</i> , 2021, 1281, 219-242.	0.8	11

#	ARTICLE	IF	CITATIONS
1014	Retromer dysfunction at the nexus of tauopathies. <i>Cell Death and Differentiation</i> , 2021, 28, 884-899.	5.0	14
1015	Frontotemporal Dementia: A Cross-Cultural Perspective. <i>Advances in Experimental Medicine and Biology</i> , 2021, 1281, 141-150.	0.8	4
1016	Molecular Mechanisms of Distinct Diseases. , 0, , .		0
1017	Mendelian and Sporadic FTD: Disease Risk and Avenues from Genetics to Disease Pathways Through In Silico Modelling. <i>Advances in Experimental Medicine and Biology</i> , 2021, 1281, 283-296.	0.8	1
1018	Early anterior cingulate involvement is seen in presymptomatic MAPT P301L mutation carriers. <i>Alzheimer's Research and Therapy</i> , 2021, 13, 42.	3.0	13
1019	Underlying pathology identified after 20 years of disease course in two cases of slowly progressive frontotemporal dementia syndromes. <i>Neurocase</i> , 2021, 27, 212-222.	0.2	4
1020	Mass spectrometry analysis of tau and amyloid β in iPSC \rightarrow derived models of Alzheimer \rightarrow s disease and dementia. <i>Journal of Neurochemistry</i> , 2021, 159, 305-317.	2.1	8
1021	Tau associated peripheral and central neurodegeneration: Identification of an early imaging marker for tauopathy. <i>Neurobiology of Disease</i> , 2021, 151, 105273.	2.1	14
1022	Tau strains shape disease. <i>Acta Neuropathologica</i> , 2021, 142, 57-71.	3.9	78
1023	Liquid \rightarrow liquid phase separation of tau: From molecular biophysics to physiology and disease. <i>Protein Science</i> , 2021, 30, 1294-1314.	3.1	54
1024	Differential accumulation of tau pathology between reciprocal F1 hybrids of rTg4510 mice. <i>Scientific Reports</i> , 2021, 11, 9623.	1.6	6
1025	Development of P301S tau seeded organotypic hippocampal slice cultures to study potential therapeutics. <i>Scientific Reports</i> , 2021, 11, 10309.	1.6	2
1026	Genome-wide CRISPR screen identifies protein pathways modulating tau protein levels in neurons. <i>Communications Biology</i> , 2021, 4, 736.	2.0	16
1027	Dietary intervention with edible medicinal plants and derived products for prevention of Alzheimer's disease: A compendium of time-tested strategy. <i>Journal of Functional Foods</i> , 2021, 81, 104463.	1.6	15
1028	Genetically engineered MAPT 10+16 mutation causes pathophysiological excitability of human iPSC-derived neurons related to 4R tau-induced dementia. <i>Cell Death and Disease</i> , 2021, 12, 716.	2.7	11
1029	Lysosome dysfunction as a cause of neurodegenerative diseases: Lessons from frontotemporal dementia and amyotrophic lateral sclerosis. <i>Neurobiology of Disease</i> , 2021, 154, 105360.	2.1	101
1030	High-content image-based analysis and proteomic profiling identifies Tau phosphorylation inhibitors in a human iPSC-derived glutamatergic neuronal model of tauopathy. <i>Scientific Reports</i> , 2021, 11, 17029.	1.6	8
1031	The role of genetics in neurodegenerative dementia: a large cohort study in South China. <i>Npj Genomic Medicine</i> , 2021, 6, 69.	1.7	7

#	ARTICLE	IF	CITATIONS
1032	Cellular and pathological heterogeneity of primary tauopathies. <i>Molecular Neurodegeneration</i> , 2021, 16, 57.	4.4	85
1033	Synaptic tau: A pathological or physiological phenomenon?. <i>Acta Neuropathologica Communications</i> , 2021, 9, 149.	2.4	30
1034	Current directions in tau research: Highlights from Tau 2020. <i>Alzheimer's and Dementia</i> , 2022, 18, 988-1007.	0.4	42
1035	Structure-based classification of tauopathies. <i>Nature</i> , 2021, 598, 359-363.	13.7	409
1036	Editorial: Tau Pathology in Neurological Disorders. <i>Frontiers in Neurology</i> , 2021, 12, 754669.	1.1	2
1037	Tau and MAPT genetics in tauopathies and synucleinopathies. <i>Parkinsonism and Related Disorders</i> , 2021, 90, 142-154.	1.1	26
1038	Genetic Therapies for Alzheimer's Disease: A Scoping Review. <i>Journal of Alzheimer's Disease</i> , 2021, 84, 491-504.	1.2	9
1039	Frequency of frontotemporal dementia-related gene variants in Turkey. <i>Neurobiology of Aging</i> , 2021, 106, 332.e1-332.e11.	1.5	1
1040	Genetic Factors That Could Affect Concussion Risk in Elite Rugby. <i>Sports</i> , 2021, 9, 19.	0.7	7
1041	Genetics of frontotemporal dementia. , 2021, , 3-16.		0
1042	Knowledge assessment and psychological impact of genetic counseling in people at risk for familial FTD. <i>Alzheimer's and Dementia: Diagnosis, Assessment and Disease Monitoring</i> , 2021, 13, e12225.	1.2	2
1043	Intranasal gene therapy for the treatment of neurological disorders. , 2021, , 351-387.		2
1044	Tau Protein and Frontotemporal Dementias. <i>Advances in Experimental Medicine and Biology</i> , 2021, 1281, 177-199.	0.8	8
1045	Corticobasal degeneration shares a common genetic background with progressive supranuclear palsy. <i>Annals of Neurology</i> , 2000, 47, 374-7.	2.8	107
1048	Alzheimer's Disease, Parkinson's Disease, and Frontotemporal Dementias: Different Manifestations of Protein Misfolding. , 2008, , 123-131.		1
1049	Cdk5 as a Drug Target for Alzheimer's Disease. , 2008, , 283-299.		2
1050	Tau Gene Mutations and Tau Pathology in Frontotemporal Dementia and Parkinsonism Linked to Chromosome 17. <i>Advances in Experimental Medicine and Biology</i> , 2001, 487, 21-37.	0.8	14
1051	Molecular Pathology of Alzheimer's Disease and Related Disorders. <i>Cerebral Cortex</i> , 1999, , 603-654.	0.6	23

#	ARTICLE	IF	CITATIONS
1052	Peripheral Markers of Alzheimer's Disease. , 2000, , 191-268.		2
1053	The A β -centric Pathway of Alzheimer's Disease. , 2007, , 5-36.		1
1054	Neurodegenerative Diseases: Insights from Drosophila and Mouse Models. Research and Perspectives in Neurosciences, 2003, , 85-103.	0.4	1
1055	Tau Mutations: Genetics and Pathogenetic Mechanisms. Research and Perspectives in Alzheimer's Disease, 2000, , 53-64.	0.1	1
1056	Tauopathies and α -Synucleinopathies. Research and Perspectives in Alzheimer's Disease, 2000, , 65-86.	0.1	5
1057	Neurodegenerative Disorders with Tauopathies: Mad Tau Diseases?. Research and Perspectives in Alzheimer's Disease, 2000, , 105-125.	0.1	1
1058	Demenz. , 2017, , 1377-1465.		1
1059	Pharmacological targets to inhibit alzheimer neurofibrillary degeneration. Journal of Neural Transmission Supplementum, 2002, , 309-319.	0.5	15
1060	Mechanism of neurofibrillary degeneration and pharmacologic therapeutic approach. , 2000, 59, 213-222.		39
1061	Ordered Assembly of Tau Protein and Neurodegeneration. Advances in Experimental Medicine and Biology, 2019, 1184, 3-21.	0.8	42
1062	Tau Interacting Proteins: Gaining Insight into the Roles of Tau in Health and Disease. Advances in Experimental Medicine and Biology, 2019, 1184, 145-166.	0.8	11
1063	Rodent Models of Tauopathies. , 2005, , 529-539.		3
1064	Progressive Supranuclear Palsy and Corticobasal Degeneration. , 2001, , 155-171.		7
1065	Application of yeast to studying amyloid and prion diseases. Advances in Genetics, 2020, 105, 293-380.	0.8	19
1066	Dementia and genetics.. , 2003, , 503-527.		6
1067	Biotin rescues mitochondrial dysfunction and neurotoxicity in a tauopathy model. Proceedings of the National Academy of Sciences of the United States of America, 2020, 117, 33608-33618.	3.3	20
1068	Clearance of intracellular tau protein from neuronal cells via VAMP8-induced secretion. Journal of Biological Chemistry, 2020, 295, 17827-17841.	1.6	17
1069	Non-Alzheimer degenerative dementias. Current Opinion in Neurology, 1998, 11, 417-427.	1.8	39

#	ARTICLE	IF	CITATIONS
1070	BEYOND AMYLOID: The Next Generation of Alzheimer's Disease Therapeutics. Molecular Interventions: Pharmacological Perspectives From Biology, Chemistry and Genomics, 2007, 7, 261-270.	3.4	46
1071	Detangling Alzheimer's Disease. Science of Aging Knowledge Environment: SAGE KE, 2003, 2003, 2oa-2.	0.9	6
1073	Frontal lobe ¹ H MR spectroscopy in asymptomatic and symptomatic <i>MAPT</i> mutation carriers. Neurology, 2019, 93, e758-e765.	1.5	18
1074	A lack of the <i>R406W tau</i> mutation in progressive supranuclear palsy and corticobasal degeneration. Neurology, 1999, 52, 404-404.	1.5	13
1075	Neurodegenerative diseases of Guam: Analysis of <i>TAU</i> . Neurology, 1999, 53, 411-411.	1.5	40
1076	Roll over Pick and tell Alzheimer the news!. Neurology, 2000, 54, 784-785.	1.5	2
1077	Tau interacts with src-family non-receptor tyrosine kinases. Journal of Cell Science, 1998, 111, 3167-3177.	1.2	395
1078	C-terminal inhibition of tau assembly in vitro and in Alzheimer's disease. Journal of Cell Science, 2000, 113, 3737-3745.	1.2	271
1079	The Unfolded Protein Response Protects from Tau Neurotoxicity In Vivo. PLoS ONE, 2010, 5, e13084.	1.1	80
1080	Progranulin deficiency induces overactivation of WNT5A expression via TNF- α /NF- κ B pathway in peripheral cells from frontotemporal dementia-linked granulin mutation carriers. Journal of Psychiatry and Neuroscience, 2016, 41, 225-239.	1.4	32
1081	Drop-on-demand Patterning of Microtubules by using a Needle Type Micro Dispenser. IEEJ Transactions on Sensors and Micromachines, 2014, 134, 114-118.	0.0	3
1082	Tau Phosphorylation and Aggregation as a Therapeutic Target in Tauopathies. CNS and Neurological Disorders - Drug Targets, 2010, 9, 727-740.	0.8	21
1083	The role of tau phosphorylation and cleavage in neuronal cell death. Frontiers in Bioscience - Landmark, 2007, 12, 733.	3.0	113
1084	Alzheimer's disease. Dialogues in Clinical Neuroscience, 2000, 2, 91-100.	1.8	74
1085	Role of tau in Alzheimer's dementia and other neurodegenerative diseases. Journal of Applied Biomedicine, 2007, 5, 1-12.	0.6	3
1086	A brief history of τ : the evolving view of the microtubule-associated protein τ in neurodegenerative diseases. , 2007, 26, 43-58.		32
1087	Pin1 Protects Against Alzheimer's Disease: One Goal, Multiple Mechanisms. , 0, , .		2
1088	Increased Signal Delays and Unaltered Synaptic Input Pattern Recognition in Layer III Neocortical Pyramidal Neurons of the rTg4510 Mouse Model of Tauopathy: A Computer Simulation Study With Passive Membrane. Frontiers in Neuroscience, 2021, 15, 721773.	1.4	0

#	ARTICLE	IF	CITATIONS
1089	Tau Post-Translational Modifications: Potentiators of Selective Vulnerability in Sporadic Alzheimer's Disease. <i>Biology</i> , 2021, 10, 1047.	1.3	14
1091	Preclinical validation of a novel oral Edaravone formulation for treatment of frontotemporal dementia. <i>Neurotoxicity Research</i> , 2021, 39, 1689-1707.	1.3	2
1092	Distinct Tau Gene Mutations Induce Specific Dysfunctions/Toxic Properties in Tau Proteins Associated With Specific FTDP-17 Phenotypes. <i>Research and Perspectives in Alzheimer's Disease</i> , 2000, , 87-104.	0.1	0
1093	Mutational Analysis of Tau in Chromosome 17-Linked Dementia. <i>Research and Perspectives in Alzheimer's Disease</i> , 2000, , 19-28.	0.1	0
1094	Missense and Splice Site Mutations in Tau Associated with FTDP-17 Multiple Pathogenic Mechanisms. <i>Research and Perspectives in Alzheimer's Disease</i> , 2000, , 29-51.	0.1	0
1095	Progress in Familial Parkinson's Disease.. <i>Journal of Clinical Biochemistry and Nutrition</i> , 2000, 28, 143-157.	0.6	0
1096	ã,žã, è>ç™¹/²ç•°ã„ç—‡. <i>Japanese Journal of Geriatrics</i> , 2001, 38, 600-604.	0.0	0
1097	Tau and neurodegenerative disease: genetics and pathogenetic mechanisms. , 2001, , 71-79.		0
1098	Rearrangement of microtubule networks by tau bearing missense mutations. , 2001, , 113-120.		0
1099	Transgenic mice overexpressing the shortest human tau isoform develop a progressive tauopathy. , 2001, , 61-69.		0
1100	Molecular Genetics and Molecular Biology of Alzheimer's Disease. , 2001, , 1187-1218.		0
1101	Tau mutations altering splicing of tau exon 10 in japanese frontotemporal dementia. , 2001, , 81-84.		0
1103	Amyotrophic lateral sclerosis/parkinsonism-dementia complex of the Kii peninsula of Japan (Kii) Tj ETQq0 0 0 rgBT /Overlock 10 Tf 50 26 molecular genetics. , 2001, , 85-93.		2
1104	Detangling Alzheimer's Disease. <i>Science of Aging Knowledge Environment: SAGE KE</i> , 2001, 2001, 2oa-2.	0.9	1
1105	Production and Analysis of Human Mutant Tau (V337M) Transgenic Mouse. <i>Advances in Behavioral Biology</i> , 2002, , 543-548.	0.2	0
1106	Interactions of Beta-Amyloid with the Formation of Neurofibrillary Tangles in Transgenic Mice. <i>Advances in Behavioral Biology</i> , 2002, , 139-144.	0.2	0
1107	Neurodegenerative Disorders. , 2002, , 31-138.		0
1108	tau Genetics in Frontotemporal Lobe Dementia, Progressive Supranuclear Palsy, and Corticobasal Degeneration. , 2003, , 325-340.		0

#	ARTICLE	IF	CITATIONS
1110	Frontotemporal Dementias: Genotypes and Phenotypes. Research and Perspectives in Alzheimer's Disease, 2005, , 103-115.	0.1	0
1111	Clinical Diagnosis of Familial Atypical Parkinsonian Disorders. , 2005, , 375-392.		0
1112	Î±- and Î²-Synucleins: two parent proteins that display similar anti-apoptotic phenotypes but distinct responses to 6-hydroxydopamine-induced toxicity. , 2005, , 103-110.		0
1113	Tauopathies. Neurological Disease and Therapy, 2005, , 651-680.	0.0	0
1114	Title is missing!. Okayama Igakkai Zasshi, 2006, 118, 193-198.	0.0	0
1116	Frontotemporal dementia " current concepts. , 2006, , 9-21.		0
1117	Tau Pathology as a Target in Alzheimer's Therapeutics. , 2007, , 223-237.		0
1119	Neurodegeneration and Dementia. , 0, , 393-400.		0
1120	The Molecular and Genetic Basis of Neurodegenerative Diseases. , 2009, , 2039-2068.		0
1122	Animal Models of Frontotemporal Dementia. Neuromethods, 2011, , 533-547.	0.2	0
1124	Pathological Validation of Animal Models of Dementia. Neuromethods, 2011, , 99-141.	0.2	1
1125	Demenz. , 2011, , 1240-1319.		0
1128	From Protein Tangles to Genetic Variants: The Central Role of Tau in Neurodegenerative Disease. , 0, ,		0
1129	Nicht-Alzheimer-Demenzen. , 2012, , 209-222.		0
1130	Brain Damage - Bridging Between Basic Research and Clinics. , 2012, ,		9
1131	Emerging Themes on Pulmonary Microvascular Endothelial Cell Microtubules and Microtubule Associated Proteins. , 2013, ,		0
1132	Genes that Modulate Longevity and Senescence. , 1999, , 11-21.		3
1133	Molekulargenetik und Molekularbiologie der Alzheimer-Krankheit. , 1999, , 117-165.		0

#	ARTICLE	IF	CITATIONS
1134	Demenz. , 2016, , 1-89.		0
1135	Frontotemporal Dementia. , 2017, , 141-175.		0
1136	Alzheimerâ€™s and perspectives from medicinal plants as therapeutics: a review. International Journal of Pharma and Bio Sciences, 2017, 8, .	0.1	0
1137	Next Generation Sequencing Data Analysis Evaluation in Patients with Parkinsonism from a Genetically Isolated Population. Genomics and Computational Biology, 2017, 3, 44.	0.7	3
1138	Prion-Like Propagation in Neurodegenerative Diseases. , 2018, , 189-242.		0
1139	Neurodegeneration and the Ordered Assembly of Tau. , 2018, , 81-98.		0
1140	Autophagy in Neurodegenerative Diseases. Cancer Drug Discovery and Development, 2019, , 197-212.	0.2	0
1142	Genetic contributions to sporadic frontotemporal dementia. , 2020, , 71-88.		1
1144	Alzheimerâ€™s disease: An update on pathophysiology and pharmacotherapy. Journal of Science and Technological Researches, 2020, 2, 19-24.	0.1	0
1145	Parkinson disease and related disorders. , 2020, , 19-30.		1
1146	Tau Gene Mutations in FTDP-17 Syndromes. , 0, , 199-213.		0
1147	Intraneuronal A β and Alzheimerâ€™s Disease. , 2008, , 297-304.		0
1148	Genetics and Neurobiology of Alzheimerâ€™s Disease and Frontotemporal Dementias. , 2006, , 1130-1141.		0
1149	Neurodegenerative Diseases. , 2008, , 531-558.		0
1150	Impact of A β -Amyloid on the Tau Pathology in Tau Transgenic Mouse and Tissue Culture Models. , 2007, , 198-215.		0
1151	Single cell gene expression profiling in Alzheimerâ€™s disease. Neurotherapeutics, 2006, 3, 302-318.	2.1	0
1153	The association of clinical phenotypes to known AD/FTD genetic risk loci and their inter-relationship. PLoS ONE, 2020, 15, e0241552.	1.1	7
1158	Genetics and biology of Alzheimer's disease and frontotemporal lobar degeneration. International Journal of Clinical and Experimental Medicine, 2010, 3, 129-43.	1.3	16

#	ARTICLE	IF	CITATIONS
1162	C9ORF72 repeat expansions and other FTD gene mutations in a clinical AD patient series from Mayo Clinic. <i>American Journal of Neurodegenerative Disease</i> , 2012, 1, 107-18.	0.1	32
1165	Human Induced Pluripotent Stem Cell Models of Frontotemporal Dementia With Tau Pathology. <i>Frontiers in Cell and Developmental Biology</i> , 2021, 9, 766773.	1.8	4
1166	Protein lysine acetylation and its role in different human pathologies: a proteomic approach. <i>Expert Review of Proteomics</i> , 2021, 18, 949-975.	1.3	12
1167	Exploring Neurofilament Light Chain and Exosomes in the Genetic Forms of Frontotemporal Dementia. <i>Frontiers in Neuroscience</i> , 2022, 16, 758182.	1.4	4
1168	Animal models in the study of Alzheimer's disease and Parkinson's disease: A historical perspective. <i>Animal Models and Experimental Medicine</i> , 2022, 5, 27-37.	1.3	10
1169	Plasma Small Extracellular Vesicles with Complement Alterations in GRN/C9orf72 and Sporadic Frontotemporal Lobar Degeneration. <i>Cells</i> , 2022, 11, 488.	1.8	7
1170	Classification of diseases with accumulation of Tau protein. <i>Neuropathology and Applied Neurobiology</i> , 2022, 48, .	1.8	32
1171	TAPPING into the potential of inducible tau/APP transgenic mice. <i>Neuropathology and Applied Neurobiology</i> , 2022, 48, .	1.8	3
1172	The pathogenic R5L mutation disrupts formation of Tau complexes on the microtubule by altering local N-terminal structure. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2022, 119, .	3.3	8
1173	Neurofibrillary tangles mediated human neuronal tauopathies: insights from fly models. <i>Journal of Genetics</i> , 2018, 97, 783-793.	0.4	1
1174	Biomarker discovery and development for frontotemporal dementia and amyotrophic lateral sclerosis. <i>Brain</i> , 2022, 145, 1598-1609.	3.7	17
1175	A human tau seeded neuronal cell model recapitulates molecular responses associated with Alzheimer's disease. <i>Scientific Reports</i> , 2022, 12, 2673.	1.6	4
1176	Concussion-Associated Gene Variant COMT rs4680 Is Associated With Elite Rugby Athlete Status. <i>Clinical Journal of Sport Medicine</i> , 2023, 33, e145-e151.	0.9	4
1177	The Molecular Basis of Spinocerebellar Ataxia Type 7. <i>Frontiers in Neuroscience</i> , 2022, 16, 818757.	1.4	5
1178	Unbiased proteomic profiling reveals the IP3R modulator AHCYL1/IRBIT as a novel interactor of microtubule-associated protein tau. <i>Journal of Biological Chemistry</i> , 2022, 298, 101774.	1.6	3
1179	Tau-induced deficits in nonsense-mediated mRNA decay contribute to neurodegeneration. <i>Alzheimer's and Dementia</i> , 2023, 19, 405-420.	0.4	8
1191	Tau gene mutations in frontotemporal dementia and parkinsonism linked to chromosome 17 (FTDP-17). <i>Neurogenetics</i> , 2000, 2, 193-205.	0.7	83
1192	Release of growth factors by neuronal precursor cells as a treatment for diseases with tau pathology. <i>Archives Italiennes De Biologie</i> , 2011, 149, 215-23.	0.1	9

#	ARTICLE	IF	CITATIONS
1193	Concussion-Associated Polygenic Profiles of Elite Male Rugby Athletes. <i>Genes</i> , 2022, 13, 820.	1.0	4
1194	Importin-Mediated Pathological Tau Nuclear Translocation Causes Disruption of the Nuclear Lamina, TDP-43 Mislocalization and Cell Death. <i>Frontiers in Molecular Neuroscience</i> , 2022, 15, 888420.	1.4	9
1195	Biological basis and psychiatric symptoms in frontotemporal dementia. <i>Psychiatry and Clinical Neurosciences</i> , 2022, 76, 351-360.	1.0	5
1196	FTD-associated mutations in Tau result in a combination of dominant and recessive phenotypes. <i>Neurobiology of Disease</i> , 2022, 170, 105770.	2.1	3
1197	Genetic Architecture of Primary Tauopathies. <i>Neuroscience</i> , 2023, 518, 27-37.	1.1	9
1198	A tough trek in the development of an anti-amyloid therapy for Alzheimer's disease: Do we see hope in the distance?. <i>Journal of the Neurological Sciences</i> , 2022, 438, 120294.	0.3	9
1199	Structures of tau and α -synuclein filaments from brains of patients with neurodegenerative diseases. <i>Neurochemistry International</i> , 2022, 158, 105362.	1.9	3
1200	Clinical Manifestations and Molecular Backgrounds of Parkinson's Disease Regarding Genes Identified From Familial and Population Studies. <i>Frontiers in Neurology</i> , 0, 13, .	1.1	6
1202	Recent Updates on the Genetics of Amyotrophic Lateral Sclerosis and Frontotemporal Dementia. <i>Molecular Neurobiology</i> , 2022, 59, 5673-5694.	1.9	25
1204	<sc><i>N</i></sc>â€œGlycosylation induced changes in tau protein dynamics reveal its role in tau misfolding and aggregation: A microsecond long molecular dynamics study. <i>Proteins: Structure, Function and Bioinformatics</i> , 2023, 91, 147-160.	1.5	5
1205	Identification and characterization of a MAPT-targeting locked nucleic acid antisense oligonucleotide therapeutic for tauopathies. <i>Molecular Therapy - Nucleic Acids</i> , 2022, 29, 625-642.	2.3	10
1207	Investigation of the role of prolines 232/233 in RTPPK motif in tau protein aggregation: An in vitro study. <i>International Journal of Biological Macromolecules</i> , 2022, 219, 1100-1111.	3.6	1
1208	Isoform-specific patterns of tau burden and neuronal degeneration in MAPT-associated frontotemporal lobar degeneration. <i>Acta Neuropathologica</i> , 2022, 144, 1065-1084.	3.9	6
1209	Biomarkers for dementia in Latin American countries: Gaps and opportunities. <i>Alzheimer's and Dementia</i> , 2023, 19, 721-735.	0.4	15
1210	Plasma Small Extracellular Vesicle Cathepsin D Dysregulation in GRN/C9orf72 and Sporadic Frontotemporal Lobar Degeneration. <i>International Journal of Molecular Sciences</i> , 2022, 23, 10693.	1.8	2
1211	Patients carrying the mutation p.R406W in MAPT present with non-conforming phenotypic spectrum. <i>Brain</i> , 0, , .	3.7	0
1212	The N-terminal disease-associated R5L Tau mutation increases microtubule shrinkage rate due to disruption of microtubule-bound Tau patches. <i>Journal of Biological Chemistry</i> , 2022, , 102526.	1.6	2
1213	The PINK1 p.Asn521Thr Variant Is Associated with Earlier Disease Onset in GRN/C9orf72 Frontotemporal Lobar Degeneration. <i>International Journal of Molecular Sciences</i> , 2022, 23, 12847.	1.8	1

#	ARTICLE	IF	CITATIONS
1214	Phosphorylated Tau in Alzheimer's Disease and Other Tauopathies. International Journal of Molecular Sciences, 2022, 23, 12841.	1.8	60
1215	Dementia and neurodegenerative disorder: An introduction. , 2023, , 1-36.		0
1216	A β and Tau Prions Causing Alzheimer's Disease. Methods in Molecular Biology, 2023, , 293-337.	0.4	6
1220	Genotype-phenotype correlation in the spectrum of frontotemporal dementia-parkinsonian syndromes and advanced diagnostic approaches. Critical Reviews in Clinical Laboratory Sciences, 2023, 60, 171-188.	2.7	2
1221	MAPT genotype-dependent mitochondrial aberration and ROS production trigger dysfunction and death in cortical neurons of patients with hereditary FTL. Redox Biology, 2023, 59, 102597.	3.9	5
1223	Aggregation of Disordered Proteins Associated with Neurodegeneration. International Journal of Molecular Sciences, 2023, 24, 3380.	1.8	16
1224	Botulinum neurotoxin A modulates the axonal release of pathological tau in hippocampal neurons. Toxicon, 2023, 228, 107110.	0.8	2
1225	Moesin is an effector of tau-induced actin overstabilization, cell cycle activation, and neurotoxicity in Alzheimer's disease. IScience, 2023, 26, 106152.	1.9	5
1227	Alzheimer's disease as a synaptopathy: Evidence for dysfunction of synapses during disease progression. Frontiers in Synaptic Neuroscience, 0, 15, .	1.3	8
1228	<i>Sut-6/NIPP1</i> modulates tau toxicity. Human Molecular Genetics, 0, , .	1.4	0
1238	The molecular pathology of neurodegenerative and psychiatric disorders. , 2023, , 3-43.		4
1239	Neurobiology of Dementia and Other Neurodegenerative Disorders. , 2023, , 1-17.		0
1246	Molecular pathology of neurodegenerative diseases by cryo-EM of amyloids. Nature, 2023, 621, 701-710.	13.7	18